[
    {
        "id": "dashboard-item-1759853783245-patient-context",
        "type": "component",
        "componentType": "PatientContext",
        "description": "'Sarah Miller (MRN: SM43850603) is a 43-year-old female patient (DOB: 1981-06-03) currently classified as high risk. Her primary diagnosis is Severe Drug-Induced Liver Injury (DILI) related to Methotrexate use.\nClinical History and Comorbidities:\nSarah has a complex medical history including Type 2 Diabetes Mellitus, Essential Hypertension, Rheumatoid Arthritis, and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH). She recently experienced an acute jaundice episode in August 2024, which is now considered resolved/improving.\nMedication Timeline and Adverse Events:\nChronic Medications: She has been on Metformin (since 2019) and Ramipril (since 2020).\nThe Adverse Event: Sarah began Methotrexate therapy for Rheumatoid Arthritis on 2024-06-03. Despite a dose reduction on 2024-07-15, the medication was discontinued on 2024-08-12 due to severe liver injury.\nTreatment: She underwent a 3-bag N-Acetylcysteine (NAC) IV protocol in August 2024 and was started on Ursodeoxycholic Acid (UDCA) on 2024-08-15.\nContraindications:\nSarah has a documented allergy/permanent contraindication to Methotrexate due to the severity of the resulting DILI.'",
        "content": {
            "title": "Patient Context",
            "component": "PatientContext",
            "props": {
                "patientData": {
                    "patient": {
                        "name": "Sarah Miller",
                        "date_of_birth": "1981-06-03",
                        "age": 43,
                        "sex": "Female",
                        "age_at_first_encounter": 43,
                        "identifiers": {
                            "mrn": "SM43850603"
                        }
                    },
                    "riskLevel": "high",
                    "primaryDiagnosis": "Severe Drug-Induced Liver Injury (Methotrexate-related)",
                    "problem_list": [
                        {
                            "name": "Type 2 Diabetes Mellitus",
                            "status": "active"
                        },
                        {
                            "name": "Essential Hypertension",
                            "status": "active"
                        },
                        {
                            "name": "Rheumatoid Arthritis",
                            "status": "active"
                        },
                        {
                            "name": "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH)",
                            "status": "active"
                        },
                        {
                            "name": "Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "status": "active"
                        },
                        {
                            "name": "Acute jaundice episode (2024-08)",
                            "status": "resolved/improving"
                        }
                    ],
                    "medication_timeline": [
                        {
                            "name": "Metformin",
                            "dose": "1000 mg",
                            "route": "PO",
                            "frequency": "BD",
                            "start": "2019-01-01"
                        },
                        {
                            "name": "Ramipril",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "daily",
                            "start": "2020-01-01"
                        },
                        {
                            "name": "Ibuprofen",
                            "dose": "variable",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2022-01-01"
                        },
                        {
                            "name": "Simethicone",
                            "dose": "standard",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2024-03-05"
                        },
                        {
                            "name": "Methotrexate",
                            "dose": "7.5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03"
                        },
                        {
                            "name": "Methotrexate (dose reduced)",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-07-15",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "N-Acetylcysteine (NAC IV)",
                            "dose": "3-bag protocol",
                            "route": "IV",
                            "frequency": "one-time protocol",
                            "start": "2024-08-12",
                            "end": "2024-08-17"
                        },
                        {
                            "name": "Ursodeoxycholic Acid (UDCA)",
                            "dose": "500 mg",
                            "route": "PO",
                            "frequency": "BID",
                            "start": "2024-08-15"
                        }
                    ],
                    "allergies": [
                        "Methotrexate (severe DILI \u2013 permanent contraindication)"
                    ]
                }
            }
        }
    },
    {
        "id": "dashboard-item-1759906219477-adverse-event-analytics",
        "type": "component",
        "componentType": "AdverseEventAnalytics",
        "description": "",
        "content": {
            "title": "Adverse Event Analytics",
            "component": "AdverseEventAnalytics",
            "props": {
                "patientData": {
                    "adverseEvents": [
                        {
                            "event": "Drug-Induced Liver Injury (DILI)",
                            "severity": "Severe",
                            "description": "Severe hepatocellular DILI caused by Methotrexate, presenting with ALT 490 U/L (12\u00d7 ULN), AST 350 U/L, and progressive jaundice."
                        },
                        {
                            "event": "Cholestatic Jaundice",
                            "severity": "Severe",
                            "description": "Bilirubin elevation from 110 to 190 \u03bcmol/L with marked jaundice; consistent with cholestatic component of acute DILI."
                        },
                        {
                            "event": "Methotrexate Toxicity",
                            "severity": "Severe",
                            "description": "Progressive hepatotoxicity after MTX initiation; ALT 185 U/L within 6 weeks; continued exposure led to severe acute DILI requiring hospitalization."
                        },
                        {
                            "event": "Acute-on-Chronic Liver Injury",
                            "severity": "Moderate\u2013Severe",
                            "description": "Acute hepatocellular necrosis superimposed on underlying MASLD/MASH, demonstrated by coarse echogenic liver on ultrasound."
                        }
                    ],
                    "rucam_ctcae_analysis": {
                        "rucam": {
                            "title": "RUCAM Scoring (Hepatocellular Pattern)",
                            "columns": [
                                "#",
                                "Parameter",
                                "Key findings from this case",
                                "Score",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "1",
                                    "Time to onset (from drug start to injury)",
                                    "MTX started 2024-06-03 \u2192 ALT rise noted by 2024-07-15 (~6 weeks)",
                                    "+2",
                                    "Typical 5\u201390 day window for idiosyncratic hepatocellular DILI."
                                ],
                                [
                                    "2",
                                    "Course after stopping the drug",
                                    "ALT decreased from 490 \u2192 420 U/L by 2024-08-15 post-MTX cessation",
                                    "+3",
                                    "Fall \u226550% within 8 days supports drug causality."
                                ],
                                [
                                    "3",
                                    "Risk factors",
                                    "Female (+0), Age 43 (+0), underlying MASLD",
                                    "0",
                                    "Neither age nor sex adds RUCAM points; MASLD is a cofactor but not scored."
                                ],
                                [
                                    "4",
                                    "Concomitant drugs",
                                    "Metformin, Ramipril, Ibuprofen (non-hepatotoxic at recorded doses)",
                                    "0",
                                    "No confounding hepatotoxic co-medication recorded."
                                ],
                                [
                                    "5",
                                    "Exclusion of non-drug causes",
                                    "Negative viral serology, negative ANA/ASMA, no biliary obstruction on ultrasound",
                                    "+2",
                                    "Competing etiologies reasonably excluded."
                                ],
                                [
                                    "6",
                                    "Previous information on hepatotoxicity",
                                    "Methotrexate well-recognized hepatotoxin with documented DILI cases",
                                    "+2",
                                    "Established hepatotoxic risk."
                                ],
                                [
                                    "7",
                                    "Response to re-exposure",
                                    "Not applicable (no re-challenge)",
                                    "0",
                                    "---"
                                ]
                            ],
                            "total_score": 9,
                            "causality_category": "Highly Probable"
                        },
                        "ctcae": {
                            "title": "CTCAE Hepatic Toxicity Scoring",
                            "columns": [
                                "Criterion",
                                "Observed / Inferred",
                                "CTCAE Grade",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "ALT/AST",
                                    "ALT 490 U/L (\u224812\u00d7 ULN), AST 350 U/L",
                                    "Grade 3",
                                    "ALT 5\u201320\u00d7 ULN = Grade 3 severity."
                                ],
                                [
                                    "Total Bilirubin",
                                    "Bilirubin peaked at 190 \u03bcmol/L (\u224811 mg/dL)",
                                    "Grade 3",
                                    ">3\u00d7 ULN and clinical jaundice."
                                ],
                                [
                                    "INR / Coagulopathy",
                                    "INR remained 1.05\u20131.1 (normal)",
                                    "Grade 1",
                                    "No synthetic dysfunction; cannot qualify as Grade 4."
                                ],
                                [
                                    "Clinical Presentation",
                                    "Severe nausea, anorexia, jaundice; no hepatic encephalopathy",
                                    "Grade 2\u20133",
                                    "Significant symptoms without CNS involvement."
                                ]
                            ],
                            "overall_grade": "CTCAE Grade 3 \u2014 Severe but not life-threatening (no ALF or encephalopathy)"
                        },
                        "reasoning": "The patient developed acute severe hepatocellular DILI approximately 6 weeks after initiating Methotrexate. The trajectory shows progressive rise in ALT from 35 to 185 to 490 U/L, accompanied by marked jaundice and cholestasis. Viral, autoimmune, and biliary causes were excluded. INR remained stable and GCS remained 15 throughout hospitalization, confirming absence of acute liver failure. Ultrasound demonstrated severe MASLD, indicating chronic vulnerability. RUCAM score is 9 (highly probable). CTCAE grading corresponds to Grade 3 hepatic injury due to elevated bilirubin and transaminases without synthetic failure. Management appropriately included immediate MTX cessation, IV NAC protocol, hepatology admission, and initiation of UDCA."
                    }
                }
            }
        }
    },
    {
        "id": "dashboard-item-1759906246155-lab-table",
        "type": "component",
        "componentType": "LabTable",
        "description": "",
        "content": {
            "title": "Lab Findings",
            "component": "LabTable",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Mild ALT elevation",
                                "Possible MASLD flare"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Prior abnormal LFTs",
                                "Chronic liver disease risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "LFT normalization",
                                "Viral/autoimmune/metabolic workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "Safe to initiate MTX"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6\u00d7 ULN)",
                                "Severe DILI warning",
                                "MTX toxicity suspected"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12\u00d7 ULN)",
                                "Bilirubin 110 \u03bcmol/L",
                                "Severe acute DILI",
                                "Emergency admission"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 \u03bcmol/L (peak cholestasis)",
                                "Ongoing severe DILI",
                                "Inpatient hepatology"
                            ]
                        }
                    }
                ],
                "labResults": [
                    {
                        "name": "ALT",
                        "value": 420,
                        "unit": "U/L",
                        "normalRange": "7-56",
                        "status": "critical",
                        "previousValue": 490,
                        "date": "2024-08-15"
                    },
                    {
                        "name": "AST",
                        "value": 350,
                        "unit": "U/L",
                        "normalRange": "10-40",
                        "status": "critical",
                        "previousValue": 350,
                        "date": "2024-08-12"
                    },
                    {
                        "name": "Total Bilirubin",
                        "value": 190,
                        "unit": "\u03bcmol/L",
                        "normalRange": "0-21",
                        "status": "critical",
                        "previousValue": 110,
                        "date": "2024-08-15"
                    },
                    {
                        "name": "INR",
                        "value": 1.1,
                        "unit": "",
                        "normalRange": "0.8-1.2",
                        "status": "normal",
                        "previousValue": 1.1,
                        "date": "2024-08-15"
                    },
                    {
                        "name": "HbA1c",
                        "value": 60,
                        "unit": "mmol/mol",
                        "normalRange": "20-42",
                        "status": "high",
                        "previousValue": 56,
                        "date": "2024-07-15"
                    }
                ]
            }
        }
    },
    {
        "id": "dashboard-item-1759906246156-lab-chart",
        "type": "component",
        "componentType": "LabChart",
        "description": "",
        "content": {
            "title": "Lab Trends",
            "component": "LabChart",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "ALT 78 U/L",
                                "Mild hepatocellular elevation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Persistently abnormal LFTs",
                                "MASLD risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "ALT normalized (35 U/L)",
                                "Workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "MTX initiation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6\u00d7 ULN)",
                                "Severe MTX toxicity warning"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12\u00d7 ULN)",
                                "Bilirubin 110 \u03bcmol/L",
                                "Severe DILI"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 \u03bcmol/L (peak)",
                                "Ongoing severe DILI"
                            ]
                        }
                    }
                ],
                "medicationTimeline": [
                    {
                        "name": "Metformin",
                        "start": "2019-01-01",
                        "dose": "1000mg BD"
                    },
                    {
                        "name": "Ramipril",
                        "start": "2020-01-01",
                        "dose": "5mg daily"
                    },
                    {
                        "name": "Methotrexate",
                        "start": "2024-06-03",
                        "end": "2024-08-12",
                        "dose": "7.5mg weekly initially; reduced to 5mg weekly on 2024-07-15"
                    },
                    {
                        "name": "Folic Acid",
                        "start": "2024-06-03",
                        "dose": "5mg weekly"
                    },
                    {
                        "name": "N-Acetylcysteine (IV)",
                        "start": "2024-08-12",
                        "end": "2024-08-17",
                        "dose": "3-bag protocol"
                    },
                    {
                        "name": "Ursodeoxycholic Acid",
                        "start": "2024-08-15",
                        "dose": "500mg BID"
                    }
                ],
                "chartData": {
                    "ALT": [
                        {
                            "date": "2024-03-05",
                            "value": 78,
                            "encounter": 1
                        },
                        {
                            "date": "2024-04-01",
                            "value": 82,
                            "encounter": 2
                        },
                        {
                            "date": "2024-05-06",
                            "value": 35,
                            "encounter": 3
                        },
                        {
                            "date": "2024-06-03",
                            "value": 32,
                            "encounter": 4
                        },
                        {
                            "date": "2024-07-15",
                            "value": 185,
                            "encounter": 5
                        },
                        {
                            "date": "2024-08-12",
                            "value": 490,
                            "encounter": 6
                        },
                        {
                            "date": "2024-08-15",
                            "value": 420,
                            "encounter": 7
                        }
                    ],
                    "AST": [
                        {
                            "date": "2024-03-05",
                            "value": 45,
                            "encounter": 1
                        },
                        {
                            "date": "2024-04-01",
                            "value": 48,
                            "encounter": 2
                        },
                        {
                            "date": "2024-05-06",
                            "value": 28,
                            "encounter": 3
                        },
                        {
                            "date": "2024-06-03",
                            "value": 25,
                            "encounter": 4
                        },
                        {
                            "date": "2024-07-15",
                            "value": 130,
                            "encounter": 5
                        },
                        {
                            "date": "2024-08-12",
                            "value": 350,
                            "encounter": 6
                        },
                        {
                            "date": "2024-08-15",
                            "value": 290,
                            "encounter": 7
                        }
                    ],
                    "Total Bilirubin": [
                        {
                            "date": "2024-03-05",
                            "value": 0.8,
                            "encounter": 1
                        },
                        {
                            "date": "2024-04-01",
                            "value": 0.9,
                            "encounter": 2
                        },
                        {
                            "date": "2024-05-06",
                            "value": 0.7,
                            "encounter": 3
                        },
                        {
                            "date": "2024-06-03",
                            "value": 0.6,
                            "encounter": 4
                        },
                        {
                            "date": "2024-07-15",
                            "value": 1.2,
                            "encounter": 5
                        },
                        {
                            "date": "2024-08-12",
                            "value": 6.4,
                            "encounter": 6
                        },
                        {
                            "date": "2024-08-15",
                            "value": 11.1,
                            "encounter": 7
                        }
                    ],
                    "INR": [
                        {
                            "date": "2024-03-05",
                            "value": 1,
                            "encounter": 1
                        },
                        {
                            "date": "2024-04-01",
                            "value": 1,
                            "encounter": 2
                        },
                        {
                            "date": "2024-05-06",
                            "value": 1,
                            "encounter": 3
                        },
                        {
                            "date": "2024-06-03",
                            "value": 1,
                            "encounter": 4
                        },
                        {
                            "date": "2024-07-15",
                            "value": 1,
                            "encounter": 5
                        },
                        {
                            "date": "2024-08-12",
                            "value": 1.1,
                            "encounter": 6
                        },
                        {
                            "date": "2024-08-15",
                            "value": 1.1,
                            "encounter": 7
                        }
                    ]
                }
            }
        }
    },
    {
        "id": "dashboard-item-1759906246157-differential-diagnosis",
        "type": "component",
        "componentType": "DifferentialDiagnosis",
        "description": "Case :\n10. What is the treatment recommendation for the likely diagnosis?\nThe recommended treatment is immediate and permanent cessation of Methotrexate, which is identified as the definitive cause of her acute hepatocellular injury. This step was implemented urgently in Encounter 6 following worsening transaminitis and new-onset jaundice (ALT 490 U/L, bilirubin 110 \u03bcmol/L). She was admitted for hospital-based management, including intravenous N-acetylcysteine (NAC) following the 3-bag protocol, consistent with guidelines for severe hepatocellular DILI even when unrelated to paracetamol. Supportive care included close monitoring of INR, neurological status, and daily LFTs. The ultrasound confirmed no obstruction, supporting the DILI diagnosis.\n\nLong-term recommendations outlined in Encounter 7 include permanent Methotrexate contraindication, initiation of Ursodeoxycholic Acid (UDCA) for cholestasis, and arranging follow-up investigations such as Fibroscan in three months to assess for fibrosis progression. Rheumatology review is required to initiate a non-hepatotoxic alternative DMARD (e.g., Hydroxychloroquine or a biologic). Overall, the treatment approach focuses on removing the offending agent, treating acute hepatocellular injury, managing cholestatic symptoms, and avoiding future hepatotoxic medications.#treatment #recommendation \n\n9. Calculate the probability of the most likely cause and rank the most likely differentials.\nBased on the full clinical picture, the most likely cause of Sarah Miller\u2019s acute liver injury is Methotrexate-induced Drug-Induced Liver Injury (DILI), with an estimated probability of 85\u201390%. This probability is strongly supported by the clear temporal relationship between MTX initiation and the rapid rise in ALT from 35 U/L to 185 U/L, followed by a peak of 490 U/L with severe jaundice. Additional supportive findings include the presence of metabolic risk factors (MASLD/MASH, obesity, diabetes), a negative viral, autoimmune, and metabolic screen, and ultrasound findings that exclude obstruction.The remaining differentials are significantly less likely. A flare of underlying MASLD/MASH is a secondary consideration (~10%) but does not typically produce the extreme hepatocellular injury seen here. Other possibilities\u2014such as NSAID-related hepatotoxicity, autoimmune hepatitis, viral hepatitis, or mechanical biliary obstruction\u2014carry very low probabilities (<3% combined) due to inconsistent clinical patterns, negative serology, normal IgG and autoimmune markers, and imaging that shows no ductal dilation or obstructive pathology. #probability #differential-diagnosis.",
        "content": {
            "title": "Differential Diagnosis",
            "component": "DifferentialDiagnosis",
            "props": {
                "patientData": {
                    "encounters": [
                        {
                            "encounter_no": 6,
                            "assessment": {
                                "impression": "Severe acute Drug-Induced Liver Injury (DILI) secondary to Methotrexate with developing cholestasis",
                                "differential": [
                                    "Methotrexate-induced hepatocellular DILI (most likely)",
                                    "Acute-on-chronic liver injury due to underlying MASLD/MASH",
                                    "Acute viral hepatitis (HBV/HCV unlikely but part of workup)",
                                    "Autoimmune hepatitis (screen previously negative)",
                                    "Mechanical biliary obstruction (excluded by ultrasound)",
                                    "Ischemic hepatitis (no shock, normal hemodynamics)",
                                    "Sepsis-associated liver injury (no fever or hemodynamic instability)"
                                ]
                            },
                            "rucam_ctcae_analysis": {
                                "rucam": {
                                    "rows": [
                                        [
                                            "1",
                                            "Time to onset from drug start",
                                            "MTX started 2024-06-03 \u2192 severe DILI by 2024-08-12 (\u224810 weeks)",
                                            "+2",
                                            "Typical 5\u201390 day window for idiosyncratic hepatocellular DILI."
                                        ],
                                        [
                                            "2",
                                            "Course after stopping drug",
                                            "ALT decreased from 490 \u2192 420 within 3 days of cessation",
                                            "+3",
                                            "Supports drug causality (fall \u226550% in <8 days expected)."
                                        ],
                                        [
                                            "5",
                                            "Exclusion of non-drug causes",
                                            "Viral hepatitis panel negative; autoimmune markers negative; ultrasound showed no obstruction",
                                            "+2",
                                            "Alternative causes convincingly excluded."
                                        ]
                                    ]
                                },
                                "reasoning": "The clinical pattern demonstrates severe hepatocellular injury with ALT 490 U/L, AST 350 U/L, and bilirubin >100 \u03bcmol/L. MTX exposure timeline fits perfectly for idiosyncratic hepatocellular DILI. Viral, autoimmune, and biliary causes were excluded through negative serology and normal biliary imaging. Hemodynamics remained stable, making ischemic hepatitis unlikely. No signs of infection to suggest sepsis-related liver injury. MASLD/MASH acted as a susceptibility factor but not the primary cause. Therefore, MTX toxicity remains the leading diagnosis."
                            }
                        }
                    ]
                }
            }
        }
    },
    {
        "id": "dashboard-item-1759906300003-single-encounter-1",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "#first encounter #first encounter.\n This is the first encounter in the patient's timeline. It is an Outpatient Visit recorded on March 5, 2024, with Dr. P. Stevens (General Practice). The patient, Sarah Miller (43, Female), presented with a chief complaint of increased fatigue over the past 4-5 months. The assessment revealed suboptimal control of Type 2 Diabetes Mellitus (HbA1c 58 mmol/mol) and Hypertension, alongside Chronic Fatigue Syndrome possibly related to Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Physical exam noted a BMI of 32.0 (Class I obesity), BP 146/92 mmHg, and mild effusion in the right wrist due to Rheumatoid Arthritis. The plan involved ordering complete LFTs and HbA1c, with a follow-up scheduled in 4 weeks to evaluate eligibility for Methotrexate (MTX) therapy.",
        "content": {
            "title": "Encounter #1 - Outpatient Visit",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 1,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-03-05T10:15:22Z",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Suboptimal control of T2DM/HTN, Chronic Fatigue Syndrome possibly related to MASLD. Diabetes control is poor with HbA1c at 58 mmol/mol, indicating long-standing hyperglycaemia and need for therapeutic adjustment.",
                        "differential": [
                            "T2DM suboptimal control",
                            "Hypertension suboptimal control",
                            "Chronic Fatigue Syndrome",
                            "MASLD"
                        ]
                    },
                    "chief_complaint": "Increased fatigue over the past 4-5 months",
                    "hpi": "Sarah Miller, a 43-year-old administrative assistant, presents with debilitating fatigue affecting work performance. She averages 6.5 hours of non-restorative sleep per night and experiences RA-related discomfort, particularly in the right wrist. She takes Ibuprofen 4-5 times per week for pain and chemically-induced frequent bloating. HbA1c from today\u2019s labs is 58 mmol/mol, confirming persistently weak glycaemic control which may be contributing to fatigue and metabolic strain.",
                    "medications_prior": [
                        {
                            "name": "Metformin",
                            "route": "Oral, unknown dose, BD frequency, for T2DM"
                        },
                        {
                            "name": "Ramipril",
                            "route": "Oral, 5mg, OD frequency, for Hypertension"
                        },
                        {
                            "name": "Ibuprofen",
                            "route": "Oral, unknown dose, taken 4-5 times per week for RA pain"
                        },
                        {
                            "name": "Simethicone",
                            "route": "Oral, unknown dose, unknown frequency, for bloating"
                        }
                    ],
                    "physical_exam": {
                        "general": "Appears non-toxic and well-perfused.",
                        "msk": "Mild effusion in right MCP joint 3, mild pain on movement.",
                        "other_systems": "Vital Signs: BP 146/92 mmHg (sitting), HR 82 bpm, RR 16/min, Temp 36.8\u00b0C, SpO\u2082 99% on room air. Anthropometrics: Height 1.64 m, Weight 86 kg (BMI 32.0 kg/m\u00b2; class I obesity). Weight reported as broadly stable over the past 12 months. Skin/Sclera: Anicteric sclerae; no chronic liver disease stigmata. Abdomen: Soft, lax, normal liver span, no tenderness. Diabetes: Persistent hyperglycaemia suspected based on elevated HbA1c and obesity."
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "Complete LFTs",
                                "HbA1c",
                                "Consider future intensification of diabetes therapy if HbA1c remains > 53 mmol/mol"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow-up in 4 weeks to evaluate LFTs and MTX eligibility.",
                            "medications_started": []
                        }
                    },
                    "reason_for_visit": "Increased fatigue"
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 1,
                "dataSource": "Electronic Health Record"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-2",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "This is the second encounter, an Outpatient visit occurring on April 1, 2024, with Dr. P. Stevens. The visit focused on reviewing abnormal liver function tests and planning Rheumatoid Arthritis treatment. The assessment highlighted an elevated ALT of 78 U/L, raising concerns for hepatocellular inflammation potentially related to MASLD. Consequently, Methotrexate initiation was deferred. The patient reported slight weight loss (0.5\u20131 kg) and was educated on the risks of liver injury. Vitals showed BP 142/90 mmHg and BMI 31.8. The plan included a comprehensive liver panel (HBsAg, HCV, ANA, Ferritin, etc.) and instructions to return in 4 weeks to review results.",
        "content": {
            "title": "Encounter #2 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 2,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-04-01T15:00:45",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Elevated ALT of 78 U/L, concerning for hepatocellular inflammation, potentially related to Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Methotrexate initiation deferred pending further investigation.",
                        "differential": [
                            "Hepatocellular inflammation",
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Viral Hepatitis",
                            "Autoimmune Hepatitis",
                            "Hemochromatosis",
                            "Alpha-1-Antitrypsin Deficiency"
                        ]
                    },
                    "chief_complaint": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment.",
                    "hpi": "Patient reports making small changes to diet and activity since the last visit, with an approximate 0.5\u20131 kg weight loss. The elevated ALT of 78 U/L was reviewed. Potential Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) was discussed as a contributing factor. Patient was educated on the significance of these results and the potential risk for liver injury if starting Methotrexate without further clearance.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 142/90 mmHg (sitting), HR 80 bpm, RR 16/min, Temp 36.7\u00b0C, SpO\u2082 99% on room air. Anthropometrics: Weight 85.5 kg (BMI 31.8 kg/m\u00b2).",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "HBsAg",
                                "HCV Ab",
                                "ANA",
                                "ASMA",
                                "Ferritin",
                                "TIBC",
                                "Full liver panel"
                            ]
                        },
                        "management": {
                            "follow_up": "Return for follow-up in 4 weeks to review investigation results. Continued monitoring and lifestyle modifications advised.",
                            "medications_started": []
                        }
                    },
                    "reason_for_visit": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 2,
                "dataSource": "BigHand"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-3",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "This is the third encounter, an Outpatient Follow-up on May 6, 2024, with Dr. P. Stevens. The purpose was to review the normalization of LFTs and reconsider Methotrexate initiation. The assessment showed LFTs had normalized (ALT 35 U/L) following ~1.5 kg weight loss and lifestyle changes; the hepatitis workup was negative. The impression was a transient elevation likely related to MASLD, and the patient was cleared for Methotrexate. Vitals included BP 140/88 mmHg and BMI 31.2. The plan instructed the patient to begin Methotrexate (7.5mg weekly) and Folic acid (5mg weekly) starting June 3, 2024, with a strict schedule for LFT and FBC monitoring every 6 weeks.\n\nCase :\n8. Has a non-invasive liver screen been performed? If so, what is the likelihood of\nother liver diseases?\n\nYes \u2014 a non-invasive liver screen has been performed, and the results strongly suggest that the likelihood of other chronic liver diseases is low. In Encounter 3, she underwent a full viral hepatitis screen (HBsAg, HBcAb, HCV Ab), autoimmune panel (ANA, ASMA, LKM-1, IgG), and metabolic testing (Ferritin, TIBC), all of which were negative or normal, effectively ruling out chronic viral, autoimmune, and metabolic liver disease. Her Fib-4 score was 0.9, which falls into the low-risk category (<1.3) for significant fibrosis or cirrhosis, further reducing suspicion of alternative chronic pathology.\n\nIn addition, the USG (ultrasound) abdomen performed during her acute presentation showed coarse, steatotic liver parenchyma with hepatomegaly, consistent with MASLD/MASH, but critically no bile duct dilatation, no ascites, no portal hypertension, no nodularity, and patent portal/hepatic veins \u2014 all of which argue against other structural liver diseases such as primary biliary cholangitis, primary sclerosing cholangitis, infiltrative disorders, or obstructive causes. Taken together, both the screening panels, Fib-4 score, and imaging findings indicate that the likelihood of other liver diseases is very low, and her course is most consistent with MASLD with superimposed Methotrexate-induced DILI rather than another chronic liver disease. #non-invasive-liver-screen #non-invasive-liver-screen.\n\n12. What other liver-related investigations are outstanding?\nSeveral liver-related investigations are still outstanding in Sarah Miller\u2019s management plan. The most important pending test is a Fibroscan, scheduled for three months after her acute DILI episode, to reassess liver stiffness and evaluate for any fibrosis progression, as documented in Encounter 7. She also requires continued daily INR monitoring until her ALT falls below 150 U/L, along with repeat LFTs to confirm recovery trends. Additionally, tasks remain active for arranging her discharge medications (including UDCA) and coordinating the rheumatology referral for a safe, non-hepatotoxic DMARD alternative. Together, these pending steps ensure full evaluation of her hepatic recovery and prevention of further liver injury. #outstanding #investigations.",
        "content": {
            "title": "Encounter #3 - Outpatient Follow-up",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 3,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-05-06T09:00:10",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Follow-up regarding normalization of liver function tests and initiation of Methotrexate for rheumatoid arthritis management. Normalization of LFTs with ALT at 35 U/L. Negative workup for chronic liver conditions. Likely transient elevation possibly related to MASLD. Cleared for Methotrexate initiation.",
                        "differential": [
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Acute self-limiting liver episode"
                        ]
                    },
                    "chief_complaint": "Follow-up regarding normalization of liver function tests (LFTs) and potential initiation of Methotrexate for rheumatoid arthritis management.",
                    "hpi": "Since the previous review, Sarah reports increased adherence to dietary advice and gentle walking most days, noting a ~1.5 kg weight loss since March. Comprehensive hepatitis workup (viral, autoimmune, metabolic) returned negative. ALT has decreased to 35 U/L, suggesting transient elevation. Patient is considered low-risk for MTX initiation.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 140/88 mmHg (sitting), HR 78 bpm, RR 15/min, Temp 36.6\u00b0C, SpO\u2082 99% on room air.",
                        "msk": "",
                        "other_systems": "Anthropometrics: Weight 84 kg (BMI 31.2 kg/m\u00b2)."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every 6 weeks",
                                "FBC every 6 weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow-up appointment set for early August to review treatment response, adherence to monitoring, and adjust plan. Instructed to begin Methotrexate on 2024-06-03. Emphasized adherence to strict 6-weekly monitoring schedule.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "weekly",
                                    "name": "Methotrexate",
                                    "route": "Unknown"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic acid",
                                    "route": "Unknown"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Follow-up for liver function tests and rheumatoid arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 3,
                "dataSource": "Electronic Health Record"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-4",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "This is the fourth encounter, an Outpatient visit on June 3, 2024, with Dr. P. Stevens. This visit marked the official initiation of Methotrexate for Rheumatoid Arthritis management. The patient confirmed understanding of the treatment regimen and hepatotoxicity risks. Physical exam showed stable weight (BMI 31.2) and BP 138/86 mmHg. The management plan confirmed the start of Methotrexate 7.5mg orally once weekly and Folic Acid 5mg weekly. A monitoring schedule was established requiring LFTs and Full Blood Count (FBC) every six weeks, with the first evaluation scheduled for July 15, 2024.",
        "content": {
            "title": "Encounter #4 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 4,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-06-03T11:30:55",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Initiation of Methotrexate for Rheumatoid Arthritis management.",
                        "differential": []
                    },
                    "chief_complaint": "Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.",
                    "hpi": "Sarah Miller presents for the initiation of Methotrexate treatment for RA. She reports her joint pain has been stable but remains a significant source of discomfort, affecting her daily activities. A thorough review of her medical history, medication adherence, and lifestyle was conducted. The patient confirms receipt and comprehension of the Methotrexate informational leaflet, indicating understanding of the treatment regimen and potential adverse effects. The decision to commence Methotrexate was made following normalization of liver function tests (LFTs) as of May 6, 2024. The patient reiterated understanding of the importance of strict compliance with the monitoring schedule due to the severe hepatotoxicity risk associated with Methotrexate.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 138/86 mmHg (sitting), HR 80 bpm, RR 15/min, Temp 36.7\u00b0C, SpO\u2082 98% on room air. Anthropometrics: Weight 84 kg (BMI 31.2 kg/m\u00b2). Weight stable compared with early May.",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every six weeks",
                                "Full Blood Count (FBC) every six weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "First LFT/FBC evaluation scheduled for July 15, 2024. Regular monitoring every six weeks for the next 6 months. Patient to contact clinic immediately if severe nausea, vomiting, or jaundice occur.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "once weekly",
                                    "name": "Methotrexate",
                                    "route": "orally"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic Acid",
                                    "route": "orally"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Initiation of Methotrexate for Rheumatoid Arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 4,
                "dataSource": "Medilogik"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-5",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "This is the fifth encounter, an Outpatient visit on July 15, 2024, with Dr. P. Stevens (Rheumatology). The patient presented for routine Methotrexate monitoring but reported new intermittent nausea and increased fatigue. The assessment identified Methotrexate-induced Drug-Induced Liver Injury (DILI) with a significantly elevated ALT of 185 U/L (4.6x ULN). While RA symptoms improved, diabetes control deteriorated (HbA1c 60 mmol/mol). Vitals showed BP 144/92 mmHg. The plan involved repeating LFTs in four weeks, advising vigilance for jaundice, and adjusting the medication regimen to Methotrexate 5mg weekly while recommending a Hepatology consultation. Next available clinical visit 15 December 2025.",
        "content": {
            "title": "Encounter #5 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 5,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-07-15T14:00:30",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Rheumatology"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Methotrexate-induced Drug-Induced Liver Injury (DILI) presenting with elevated ALT (185 U/L, 4.6x ULN), with new intermittent nausea and increased fatigue. Rheumatoid arthritis symptoms are improving on Methotrexate. Diabetes control has deteriorated with HbA1c rising to 60 mmol/mol, signalling worsening glycaemia during MTX therapy and possible contribution to fatigue.",
                        "differential": [
                            "Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "Underlying MASLD risk factors"
                        ]
                    },
                    "chief_complaint": "Routine Methotrexate (MTX) monitoring. Reports of new intermittent nausea and increased fatigue.",
                    "hpi": "Sarah Miller, a 43-year-old female, presents for routine Methotrexate monitoring. She reports ~1 kg unintentional weight loss over the past month, attributed to reduced appetite and intermittent nausea, primarily in the evenings. No vomiting or diarrhea. Fatigue levels have returned to pre-MTX initiation severity. Rheumatoid arthritis symptoms have significantly improved with diminished joint pain and increased daily function since starting Methotrexate. Recent labs show ALT elevated to 185 U/L (4.6x ULN). HbA1c has worsened to 60 mmol/mol, indicating declining diabetes control despite weight loss.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 144/92 mmHg (sitting), HR 88 bpm, RR 16/min, Temp 36.8\u00b0C, SpO\u2082 98% on room air.",
                        "msk": "Joint pain has diminished.",
                        "other_systems": "Weight 83 kg (BMI 30.8 kg/m\u00b2). Despite some weight reduction, diabetes control is worsening with higher HbA1c and increased metabolic fatigue."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "Repeat liver function tests in four weeks",
                                "HbA1c monitoring recommended due to recent deterioration"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow up in four weeks. Advised to remain vigilant for any worsening of symptoms or new signs of liver dysfunction such as jaundice, further exacerbated fatigue, or darker urine. Ensure adherence to adjusted Methotrexate regimen. Attend Hepatology consultation.",
                            "medications_started": [
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Methotrexate",
                                    "route": ""
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Routine Methotrexate monitoring and management of new symptoms of nausea and fatigue, and elevated liver enzymes."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 5,
                "dataSource": "Nervecentre"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-6",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "\nHave there been significant changes in her health? E.g. weight, blood pressure.\nHave there been significant changes in her health? E.g. weight, blood pressure.\nEncounter Document Description: Urgent ED Review (Encounter #6)\nThis document details Encounter #6, an urgent Emergency Department visit for Sarah Miller on 2024-08-12. The visit was prompted by new-onset jaundice, dark urine, and severe nausea. The provider, Dr. P. Stevens, diagnosed Severe, Acute Drug-Induced Liver Injury (DILI).\nKey Clinical Data Points:\nVitals: BP 132/88 mmHg, HR 102 bpm (tachycardic), Temp 37.3\u00b0C, SpO\u2082 97%.\nAnthropometrics: Current Weight 81.5 kg (BMI 30.3 kg/m \u00b2).\nSymptoms: Anorexia, nausea, jaundice.\nClinical Q&A:\nQ: Have there been significant changes in her health? E.g. weight, blood pressure.\nA:\nWeight: Yes. The patient reported a significant weight loss of approximately 4.5 kg over the past 4\u20136 weeks. This is attributed to persistent nausea and anorexia. Her current weight is recorded at 81.5 kg.\nBlood Pressure: Her blood pressure was recorded at 132/88 mmHg during this visit. (Note: This document provides a snapshot; comparison to baseline requires reviewing previous encounter logs).\nGeneral Health Status: There is a marked acute decline in health characterized by new onset jaundice and tachycardia (HR 102 bpm), indicating physiological stress resulting from severe liver toxicity.",
        "content": {
            "title": "Encounter #6 - Urgent Review",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 6,
                    "meta": {
                        "visit_type": "Emergency Department (ED)",
                        "date_time": "2024-08-12T14:00:00",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "General Practitioner"
                        },
                        "ui_risk_color": "red"
                    },
                    "assessment": {
                        "impression": "Severe, Acute Drug-Induced Liver Injury (DILI) with developing cholestasis.",
                        "differential": [
                            "Mechanical obstruction (e.g., choledocholithiasis)"
                        ]
                    },
                    "chief_complaint": "Urgent review for new onset jaundice, dark urine, and constant, severe nausea leading to anorexia.",
                    "hpi": "Patient presented with new onset jaundice, dark urine, and severe nausea leading to anorexia. Initial ED vital signs: BP 132/88 mmHg (sitting), HR 102 bpm, RR 18/min, Temp 37.3\u00b0C, SpO\u2082 97% on room air. Weight 81.5 kg (BMI 30.3 kg/m\u00b2). Patient reported significant weight loss of approximately 4.5 kg over the past 4\u20136 weeks due to nausea and anorexia. Jaundice noted upon waking, dark urine observed. Symptoms are severe and persistent. Laboratory analysis revealed significantly elevated ALT levels and bilirubin of 110 \u03bcmol/L, indicating severe cholestasis. INR was stable at 1.1.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "route": "Oral"
                        }
                    ],
                    "physical_exam": {
                        "general": "Jaundice noted. Patient appears anorectic."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "USG Abdomen Complete - STAT (Accession Number: USG-240812-001). Report indicates severe MASH/MASLD, no mechanical obstruction. Impression: Severe hepatocellular DILI superimposed on advanced chronic liver disease (MASH)."
                            ],
                            "labs": [
                                "ALT levels elevated",
                                "Bilirubin levels elevated to 110 \u03bcmol/L",
                                "INR stable at 1.1"
                            ]
                        },
                        "management": {
                            "follow_up": "Close follow-up post-hospital discharge to reassess liver function and re-evaluate RA treatment plan, considering contraindication for future Methotrexate use.",
                            "medications_started": [
                                {
                                    "name": "N-acetylcysteine (NAC)",
                                    "route": "IV Infusion (3-bag protocol, 85kg weight)"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "New onset jaundice, dark urine, severe nausea, and anorexia, concerning for acute liver injury."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 1,
                "dataSource": "ICE/VueExplore"
            }
        }
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-7",
        "type": "component",
        "componentType": "SingleEncounterDocument",
        "description": "#latest encounter #latest encounter.\n This is the seventh and latest encounter recorded for the patient. It is an Inpatient visit at Hepatology Ward B on August 15, 2024. Dr. R. Sharma (Consultant Hepatologist) reviewed the patient on Day 3 of admission. The diagnosis was confirmed as Severe Drug-Induced Liver Injury (DILI) secondary to Methotrexate (RUCAM score 9/10) on a background of MASH. The patient remained significantly jaundiced (Bilirubin 190 \u03bcmol/L) but was alert (GCS 15) with no signs of hepatic encephalopathy. ALT levels were declining, and INR was stable. The management plan included Ursodeoxycholic Acid (UDCA) 500mg twice daily, daily INR evaluations, neurological checks, and a scheduled Fibroscan in three months. Rheumatology was advised to switch to non-hepatotoxic alternatives for RA.",
        "content": {
            "title": "Encounter #7 - Inpatient Hepatology Ward B",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 7,
                    "meta": {
                        "visit_type": "Inpatient",
                        "date_time": "2024-08-15T10:00:48",
                        "provider": {
                            "name": "Dr. R. Sharma",
                            "specialty": "Consultant Hepatologist"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Severe Drug-Induced Liver Injury (DILI) secondary to Methotrexate, with a RUCAM score of 9/10, indicating a high likelihood of causation. No features of Acute-on-Chronic Liver Failure (ACLF). Underlying Metabolic Associated Steatotic Hepatitis (MASH).",
                        "differential": []
                    },
                    "chief_complaint": "Severe Drug-Induced Liver Injury (DILI)",
                    "hpi": "The patient is reviewed on Day 3 of her hospital admission following severe DILI. Methotrexate was stopped immediately upon recognizing it as the causative agent. Sarah remains significantly jaundiced; however, nausea has shown slight improvement since admission. Vital neurological signs include a stable Glasgow Coma Scale (GCS) score of 15, with no evidence of hepatic encephalopathy (HE); absence of asterixis or cognitive impairment. The ALT level, though elevated at 420 U/L, is beginning to decline, suggesting a positive response to the cessation of Methotrexate. Crucially, the INR remains stable at 1.1, indicating preserved liver synthetic function. These clinical findings collectively confirm a diagnosis of severe, cholestatic DILI in a patient with underlying Metabolic Associated Steatotic Hepatitis (MASH), markedly susceptible to hepatotoxic insults.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Sarah exhibits pronounced jaundice, evidenced by a total bilirubin level of 190 \u03bcmol/L. Despite this, she appears alert and reports moderate comfort under current care measures. Vital Signs (ward review): BP 128/82 mmHg, HR 96 bpm, RR 16/min, Temp 37.0\u00b0C, SpO\u2082 97% on room air. Anthropometrics: Weight 81 kg (BMI 30.1 kg/m\u00b2). No significant interval weight change since admission.",
                        "msk": "",
                        "other_systems": "CNS Examination: She is fully oriented, demonstrating no neurological deficits. GCS remains a reassuring 15 with negative neurological signs including asterixis, tremor, and speech abnormalities. Cardio/Pulmonary: Vital signs are stable with no indications of fluid overload, pulmonary distress, or hepatorenal syndrome. Abdominal Examination: The abdomen is soft and non-tender. The liver edge is not easily palpable due to Sarah's body habitus, yet no tenderness is detected upon examination."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "Fibroscan in three months"
                            ],
                            "labs": [
                                "Daily INR evaluations until ALT levels fall below 150 U/L",
                                "Neurological assessments every four hours"
                            ]
                        },
                        "management": {
                            "follow_up": "Arrange a Fibroscan (Liver Stiffness Measurement) in three months to assess fibrosis arising from chronic MASH and the acute DILI event. Coordinate with Rheumatology for the initiation of a non-hepatotoxic DMARD alternative, such as Hydroxychloroquine or a biologic, to manage RA without compromising liver health.",
                            "medications_started": [
                                {
                                    "dose": "500mg",
                                    "frequency": "twice daily",
                                    "name": "Ursodeoxycholic Acid (UDCA)",
                                    "route": ""
                                },
                                {
                                    "dose": "",
                                    "frequency": "",
                                    "name": "Folic Acid",
                                    "route": ""
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Review on Day 3 of hospital admission following severe DILI."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 7,
                "dataSource": "Nervecentre"
            }
        }
    },
    {
        "id": "raw-medilogik-ems-colonoscopy",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "Medilogik DMARD Safety Monitoring with Highlights",
        "content": {
            "title": "Medilogik - Outpatient",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 4,
                "date": "2024-06-03",
                "visitType": "Outpatient",
                "provider": "Dr. P. Stevens",
                "specialty": "MRCGP",
                "rawText": "\n**Medilogik**\n**Task Group:** DMARD Safety Monitoring & Patient Engagement Workflow\n**Created By:** Dr. P. Stevens, MD, MRCGP\n**Date Created:** 2024-06-03\n**Priority:** **High**\n**Status:** Active\n**Task ID:** **MTX_MONITOR_SM_01_RECUR**\n**Associated Encounter:** Outpatient \u2013 Methotrexate Initiation Consultation\n\n---\n\n## **1. Task Description (Expanded)**\n\n\u201cEstablish a comprehensive Methotrexate (MTX) monitoring workflow for Sarah Miller following initiation of 7.5 mg weekly MTX therapy for Rheumatoid Arthritis.\nThe objective is to ensure safe continuation of MTX, early detection of hepatotoxicity, cytopenias, or intolerance, and reinforcement of adherence to patient education and safety-netting protocols.\u201d\n\n---\n\n# **2. Monitoring Schedule (Detailed)**\n\n### **Initial Post-Initiation Assessment**\n\n* **Due Date:** **2024-07-15**\n* **Tests Required:**\n\n  * Full Liver Function Panel (ALT, AST, ALP,  Bilirubin, INR)\n  * Full Blood Count (FBC)\n* **Purpose:**\n\n  * Assess early hepatic response to MTX\n  * Detect early cytopenias\n  * Evaluate need for dose adjustment or pause\n\n---\n\n### **Ongoing Routine Monitoring**\n\n* **Frequency:** Every **6 weeks**\n* **Duration:** First 6 months (June\u2013December 2024)\n* **Tests at each interval:**\n\n  * **LFT**\n  * **FBC**\n  * **Renal Profile (U+E)**\n  * **CRP (optional, if RA control uncertain)**\n\n### **Post-6-Month Monitoring**\n\n* If stable \u2192 move to **every 8\u201312 weeks** per DMARD safety protocol.\n\n---\n\n# **3. Medilogik Auto-Alert Configuration**\n\n### **High-Priority Auto-Alerts (Immediate clinician notification)**\n\n* **ALT > 2\u00d7 ULN (>80 U/L)**\n* **AST > 2\u00d7 ULN**\n* **Platelets < 150 \u00d710\u2079/L**\n* **Neutrophils <1.5 \u00d710\u2079/L**\n* **WBC <3.0 \u00d710\u2079/L**\n* **Bilirubin rising trend across two tests**\n\n**Action Trigger:**\n\u2192 Display interruptive alert in Medilogik clinician inbox\n\u2192 Flag patient chart with **\u201cDMARD Safety Alert \u2013 Review Required\u201d**\n\n---\n\n### **Moderate-Priority Auto-Alerts**\n\n* **Gradual ALT rise but < 2\u00d7 ULN**\n* **New macrocytosis**\n* **eGFR decline**\n  \u2192 Routed to GP monitoring pool for review within 72 hours.\n\n---\n\n# **4. Associated Patient Education Tasks**\n\n### **Patient Education Pack Delivery**\n\n* Includes:\n\n  * MTX Information Leaflet (British Society for Rheumatology standard)\n  * Liver toxicity symptoms sheet\n  * Medication schedule card (MTX + folic acid)\n* Marked as **Completed \u2013 Provided in clinic, 2024-06-03**\n\n---\n\n### **Compliance Check Call**\n\n* **Scheduled:** 7 days post initiation (2024-06-10)\n* **Purpose:**\n\n  * Confirm correct dosing (once weekly only)\n  * Verify folic acid timing\n  * Screen for early side effects\n* Responsible Team: GP Support / Clinical Pharmacist\n\n---\n\n### **Alcohol Intake Advisory**\n\n* Task to review patient\u2019s alcohol intake at each monitoring appointment\n* Documented baseline: \u201cPatient consumes 12 units/week\u201d\n* Goal: Reduce to < 6 units/week for MTX safety\n\n---\n\n# **5. Clinical Safety & Governance Notes**\n\n* MTX initiation authorized based on:\n\n  * ALT normalization (ALT 35)\n  * Negative viral hepatitis screen\n  * Negative autoimmune hepatitis screen\n  * Normal synthetic liver profile\n  * Low Fib-4 (0.9)\n\n* MASLD acknowledged as background risk; enhanced vigilance maintained.\n\n* MTX classified as a **high-risk drug**, requiring strict adherence to monitoring timeline.\n\n* Medilogik will:\n\n  * Log missed tests\n  * Auto-generate overdue notices after 48 hours\n  * Escalate persistent failures to GP clinical lead\n\n---\n\n# **6. Follow-Up & Tracking**\n\n### **Next Steps**\n\n* **Next scheduled test:** 2024-07-15\n* **Next clinician review:** Early August appointment already booked\n* **Rheumatology liaison:** If RA control insufficient at 12 weeks, Medilogik flags GP to consider rheumatology review\n\n### **Dashboard Integration**\n\nMedilogik integrates with the practice DMARD dashboard:\n\n* Displays latest LFT/FBC trends\n* Risk colour-coding (Green \u2192 Amber \u2192 Red)\n* Task completion metrics\n\nSarah is currently classified as:\n**Amber \u2013 New MTX Start (requires intensified monitoring)**\n\n---\n",
                "dataSource": "Medilogik",
                "highlights": [
                    {
                        "text": "ALT > 2\u00d7 ULN (>80 U/L)",
                        "color": "red"
                    },
                    {
                        "text": "AST > 2\u00d7 ULN",
                        "color": "red"
                    },
                    {
                        "text": "Bilirubin rising trend across two tests",
                        "color": "red"
                    },
                    {
                        "text": "Gradual ALT rise but < 2\u00d7 ULN",
                        "color": "yellow"
                    },
                    {
                        "text": "Patient consumes 12 units/week",
                        "color": "yellow"
                    },
                    {
                        "text": "MTX initiation authorized based on: ALT normalization (ALT 35)",
                        "color": "green"
                    },
                    {
                        "text": "Negative viral hepatitis screen",
                        "color": "green"
                    },
                    {
                        "text": "Negative autoimmune hepatitis screen",
                        "color": "green"
                    },
                    {
                        "text": "Normal synthetic liver profile",
                        "color": "green"
                    },
                    {
                        "text": "Low Fib-4 (0.9)",
                        "color": "green"
                    },
                    {
                        "text": "MASLD acknowledged as background risk; enhanced vigilance maintained.",
                        "color": "yellow"
                    },
                    {
                        "text": "MTX classified as a high-risk drug, requiring strict adherence to monitoring timeline.",
                        "color": "yellow"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-viper-ultrasound-ivc",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "Viper MTX Safety Clearance with Highlights",
        "content": {
            "title": "Viper - Encounter 3",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 3,
                "date": "2024-05-06",
                "visitType": "Clinical Review",
                "provider": "Dr. P. Stevens",
                "specialty": "MRCGP",
                "rawText": "\n# **VIPER**\n\n**Module:** Clinical Review & Planning Module\n**Entry Type:** GP MTX Safety Clearance \u2013 Structured Review\n**Author:** Dr. P. Stevens, MD, MRCGP\n**Date:** 2024-05-06\n**Linked Encounter:** Outpatient Review \u2013 Pre-DMARD Evaluation\n**Source:** VIPER Clinical Decision Support Engine\n\n---\n\n### **V \u2013 Verification of Clinical Data**\n\n* Reviewed full laboratory panel from 2024-05-06:\n\n  * **ALT 35 U/L (normal)**\n  * **AST 30 U/L (normal)**\n  * **ALP 102 U/L (normal)**\n  * **Bilirubin normal**\n  * **INR normal**\n* Reviewed all chronic hepatitis screening results:\n\n  * **HBsAg negative, HBcAb negative, HCV Ab negative**\n* Reviewed autoimmune screen:\n\n  * **ANA negative, ASMA negative, LKM-1 negative, IgG normal**\n* Reviewed metabolic panel:\n\n  * **Ferritin normal, transferrin saturation normal, A1AT normal**\n* Reviewed Fib-4 Index: **0.9 (low risk)**\n* Confirmed no hepatotoxic concomitant medications apart from intermittent NSAID use, now minimised.\n\n---\n\n### **I \u2013 Interpretation of Risk**\n\n* **All reversible causes of transaminitis previously present have resolved.**\n* Hepatocellular injury noted in Encounter 1 is confirmed as **transient MASLD flare**, not chronic liver disease.\n* Negative viral, autoimmune, and metabolic screen eliminates major contraindications to MTX.\n* Current liver function is **stable and low-risk** for MTX initiation.\n* MASLD remains a background risk factor, but risk is mitigated by:\n\n  * recent weight-loss efforts\n  * improved diet\n  * reduced alcohol use\n* Overall risk classification: **Low\u2013Moderate**, acceptable for MTX with strict monitoring.\n\n---\n\n### **P \u2013 Planning**\n\n* Approve **Methotrexate initiation at 7.5 mg once weekly**, start date **2024-06-03**.\n* Prescribe **Folic Acid 5 mg weekly**, 24h post-dose.\n* Implement a **strict 6-weekly LFT + FBC monitoring protocol**:\n\n  * 1st scheduled test: **2024-07-15**\n  * Auto-alerts configured for:\n\n    * ALT > 2\u00d7 ULN\n    * Platelets < 150 \u00d7 10\u2079/L\n    * Neutrophils < 1.5 \u00d7 10\u2079/L\n\n---\n\n### **E \u2013 Escalation & Safety Netting**\n\n* Safety-net advice provided:\n\n  * Stop MTX immediately and contact clinic if **jaundice, dark urine, severe fatigue, vomiting**, or RUQ pain develop.\n  * Avoid NSAIDs unless absolutely required; paracetamol preferred.\n  * Abstain from alcohol entirely during first 6 weeks.\n* Discussed MASLD contribution and the need for ongoing lifestyle improvement.\n* No current indication for hepatology referral.\n* Escalation trigger: persistent ALT > 1.5\u00d7 ULN at any follow-up.\n\n---\n\n### **R \u2013 Recommendations (Final VIPER Output)**\n\n\u201cFollowing full review of all laboratory, clinical, and risk-stratification data, the patient is **safe to commence Methotrexate** under a structured monitoring schedule. No evidence of chronic liver disease or absolute contraindication. Continue MASLD lifestyle management. LFTs must be followed rigorously every 6 weeks. Patient educated on red-flag symptoms and agrees to the plan.\u201d\n\n---\n",
                "dataSource": "Viper",
                "highlights": [
                    {
                        "text": "ALT 35 U/L (normal)",
                        "color": "green"
                    },
                    {
                        "text": "AST 30 U/L (normal)",
                        "color": "green"
                    },
                    {
                        "text": "ALP 102 U/L (normal)",
                        "color": "green"
                    },
                    {
                        "text": "Bilirubin normal",
                        "color": "green"
                    },
                    {
                        "text": "INR normal",
                        "color": "green"
                    },
                    {
                        "text": "HBsAg negative, HBcAb negative, HCV Ab negative",
                        "color": "green"
                    },
                    {
                        "text": "ANA negative, ASMA negative, LKM-1 negative, IgG normal",
                        "color": "green"
                    },
                    {
                        "text": "Ferritin normal, transferrin saturation normal, A1AT normal",
                        "color": "green"
                    },
                    {
                        "text": "* Reviewed Fib-4 Index: **0.9 (low risk)**",
                        "color": "green"
                    },
                    {
                        "text": "Confirmed no hepatotoxic concomitant medications apart from intermittent NSAID use, now minimised.",
                        "color": "yellow"
                    },
                    {
                        "text": "All reversible causes of transaminitis previously present have resolved.",
                        "color": "green"
                    },
                    {
                        "text": "* Hepatocellular injury noted in Encounter 1 is confirmed as **transient MASLD flare**, not chronic liver disease.",
                        "color": "green"
                    },
                    {
                        "text": "Negative viral, autoimmune, and metabolic screen eliminates major contraindications to MTX.",
                        "color": "green"
                    },
                    {
                        "text": "* Current liver function is **stable and low-risk** for MTX initiation.",
                        "color": "green"
                    },
                    {
                        "text": "MASLD remains a background risk factor, but risk is mitigated by:",
                        "color": "yellow"
                    },
                    {
                        "text": "recent weight-loss efforts",
                        "color": "yellow"
                    },
                    {
                        "text": "improved diet",
                        "color": "yellow"
                    },
                    {
                        "text": "reduced alcohol use",
                        "color": "yellow"
                    },
                    {
                        "text": "* Overall risk classification: **Low\u2013Moderate**, acceptable for MTX with strict monitoring.",
                        "color": "yellow"
                    },
                    {
                        "text": "* Auto-alerts configured for:\n\n    * ALT > 2\u00d7 ULN",
                        "color": "red"
                    },
                    {
                        "text": "* Stop MTX immediately and contact clinic if **jaundice, dark urine, severe fatigue, vomiting**, or RUQ pain develop.",
                        "color": "red"
                    },
                    {
                        "text": "Avoid NSAIDs unless absolutely required; paracetamol preferred.",
                        "color": "yellow"
                    },
                    {
                        "text": "Abstain from alcohol entirely during first 6 weeks.",
                        "color": "yellow"
                    },
                    {
                        "text": "No current indication for hepatology referral.",
                        "color": "green"
                    },
                    {
                        "text": "Escalation trigger: persistent ALT > 1.5\u00d7 ULN at any follow-up.",
                        "color": "yellow"
                    },
                    {
                        "text": "the patient is **safe to commence Methotrexate** under a structured monitoring schedule.",
                        "color": "green"
                    },
                    {
                        "text": "No evidence of chronic liver disease or absolute contraindication.",
                        "color": "green"
                    },
                    {
                        "text": "Continue MASLD lifestyle management.",
                        "color": "yellow"
                    },
                    {
                        "text": "LFTs must be followed rigorously every 6 weeks.",
                        "color": "yellow"
                    },
                    {
                        "text": "Patient educated on red-flag symptoms and agrees to the plan.",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-lab-data-encounter-1",
        "type": "component",
        "componentType": "ICELabData",
        "description": "ICE Laboratory System - Encounter 1 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 1",
            "component": "Lab",
            "props": {
                "encounters": [
                    {
                        "encounter": 1,
                        "tests": [
                            {
                                "name": "ALT",
                                "result": "78",
                                "unit": "U/L",
                                "reference_range": "< 40",
                                "flag": "H"
                            },
                            {
                                "name": "AST",
                                "result": "55",
                                "unit": "U/L",
                                "reference_range": "< 35",
                                "flag": "H"
                            },
                            {
                                "name": "ALP",
                                "result": "105",
                                "unit": "U/L",
                                "reference_range": "30-130",
                                "flag": ""
                            },
                            {
                                "name": "Bilirubin (Total)",
                                "result": "12",
                                "unit": "\u03bcmol/L",
                                "reference_range": "< 21",
                                "flag": ""
                            },
                            {
                                "name": "INR",
                                "result": "1.0",
                                "unit": "",
                                "reference_range": "0.8-1.2",
                                "flag": ""
                            },
                            {
                                "name": "HbA1c",
                                "result": "58",
                                "unit": "mmol/mol",
                                "reference_range": "< 48",
                                "flag": "H"
                            },
                            {
                                "name": "FBC: Platelets",
                                "result": "250",
                                "unit": "x10^9/L",
                                "reference_range": "150-400",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-lab-data-encounter-3",
        "type": "component",
        "componentType": "ICELabData",
        "description": "'Case :\n7. From her other blood results, is there any evidence of liver cirrhosis?\nThere is no evidence to suggest established liver cirrhosis. Her synthetic liver function remains intact throughout \u2014 INR stays normal (1.0\u20131.1), and platelet counts are normal (250\u00d710\u2079/L), which strongly argues against portal hypertension or decompensated cirrhosis. The Fib-4 score of 0.9 in Encounter 3 places her firmly in the low-risk category for significant fibrosis or cirrhosis, and although a later Fib-4 rises to 1.8, this is during acute Methotrexate-induced liver injury and does not reflect chronic fibrosis. Additionally, ultrasound imaging shows steatotic/MASH changes without nodularity, ascites, or portal vein abnormalities, further excluding cirrhosis.\n\nWhile she does experience severe acute DILI with marked transaminitis and cholestasis later in her course, these represent acute hepatocellular injury, not chronic cirrhotic dysfunction. Overall, the combination of normal INR, normal platelets, low pre-injury Fib-4, and imaging without cirrhotic features provides strong, consistent evidence that she does not have cirrhosis.\n'",
        "content": {
            "title": "ICE Lab - Encounter 3",
            "component": "Lab",
            "props": {
                "encounters": [
                    {
                        "encounter": 3,
                        "tests": [
                            {
                                "name": "ALT",
                                "result": "35",
                                "unit": "U/L",
                                "reference_range": "< 40",
                                "flag": ""
                            },
                            {
                                "name": "AST",
                                "result": "30",
                                "unit": "U/L",
                                "reference_range": "< 35",
                                "flag": ""
                            },
                            {
                                "name": "HBsAg/HCV Ab",
                                "result": "Negative",
                                "unit": "N",
                                "reference_range": "N",
                                "flag": ""
                            },
                            {
                                "name": "ANA/ASMA",
                                "result": "Negative",
                                "unit": "N",
                                "reference_range": "N",
                                "flag": ""
                            },
                            {
                                "name": "Fib-4 Index",
                                "result": "0.9",
                                "unit": "",
                                "reference_range": "< 1.3",
                                "flag": ""
                            },
                            {
                                "name": "HbA1c",
                                "result": "56",
                                "unit": "mmol/mol",
                                "reference_range": "<48",
                                "flag": "H"
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-lab-data-encounter-5",
        "type": "component",
        "componentType": "ICELabData",
        "description": "ICE Laboratory System - Encounter 5 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 5",
            "component": "LabPage",
            "props": {
                "encounters": [
                    {
                        "encounter": 5,
                        "tests": [
                            {
                                "name": "ALT",
                                "result": "185",
                                "unit": "U/L",
                                "reference_range": "< 40",
                                "flag": "H"
                            },
                            {
                                "name": "AST",
                                "result": "130",
                                "unit": "U/L",
                                "reference_range": "< 35",
                                "flag": "H"
                            },
                            {
                                "name": "Bilirubin (Total)",
                                "result": "15",
                                "unit": "$\\\\",
                                "reference_range": "< 21",
                                "flag": ""
                            },
                            {
                                "name": "HbA1c",
                                "result": "60",
                                "unit": "mmol/mol",
                                "reference_range": "<48",
                                "flag": "H"
                            },
                            {
                                "name": "INR",
                                "result": "1.05",
                                "unit": "",
                                "reference_range": "0.8-1.2",
                                "flag": ""
                            },
                            {
                                "name": "Fib-4 Score",
                                "result": "1.8",
                                "unit": "",
                                "reference_range": "< 1.3",
                                "flag": "H"
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-lab-data-encounter-6",
        "type": "component",
        "componentType": "ICELabData",
        "description": "ICE Laboratory System - Encounter 6 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 6",
            "component": "ICE LLM Lab",
            "props": {
                "encounters": [
                    {
                        "encounter": 6,
                        "tests": [
                            {
                                "name": "ALT",
                                "result": "490",
                                "unit": "U/L",
                                "reference_range": "< 40",
                                "flag": "H"
                            },
                            {
                                "name": "AST",
                                "result": "350",
                                "unit": "U/L",
                                "reference_range": "< 35",
                                "flag": "H"
                            },
                            {
                                "name": "INR",
                                "result": "1.1",
                                "unit": "ratio",
                                "reference_range": "0.8-1.2",
                                "flag": ""
                            },
                            {
                                "name": "Bilirubin (Total)",
                                "result": "110",
                                "unit": "\u03bcmol/L",
                                "reference_range": "< 21",
                                "flag": "H"
                            },
                            {
                                "name": "MELD ",
                                "result": "9",
                                "unit": "",
                                "reference_range": "",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-lab-data-encounter-7",
        "type": "component",
        "componentType": "ICELabData",
        "description": "ICE Laboratory System - Encounter 7 Lab Results",
        "content": {
            "title": "ICE Lab - Encounter 7",
            "component": "Lab",
            "props": {
                "encounters": [
                    {
                        "encounter": 7,
                        "tests": [
                            {
                                "name": "ALT",
                                "result": "420",
                                "unit": "U/L",
                                "reference_range": "< 40",
                                "flag": "H"
                            },
                            {
                                "name": "INR",
                                "result": "1.1",
                                "unit": "",
                                "reference_range": "0.8-1.2",
                                "flag": ""
                            },
                            {
                                "name": "Bilirubin (Total)",
                                "result": "190",
                                "unit": "\b0\b",
                                "reference_range": "< 21",
                                "flag": "H"
                            },
                            {
                                "name": "MELD Score",
                                "result": "10",
                                "unit": "",
                                "reference_range": "",
                                "flag": ""
                            }
                        ]
                    }
                ]
            }
        }
    },
    {
        "id": "raw-nervecentre-encounter-1",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "Nervecentre Lab Alert with Highlighted Key Information",
        "content": {
            "title": "Nervecentre - Encounter 1",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 1,
                "date": "2024-03-05",
                "visitType": "Outpatient",
                "provider": "Dr. P. Stevens",
                "specialty": "MRCGP",
                "rawText": "### Nervecentre\n\n**Module:** Laboratory Alerting & Task Management\n**Event Type:** Automated Laboratory Alert \u2013 LFT Derangement \n\n---\n\n#### 1. Alert Event Summary\n\n* **System Alert ID:** NC-LFT-20240305-001\n* **Patient:** Sarah Miller (MRN: SM43850603, DOB: 1981-06-03, Age 43, F) \n* **Linked Encounter:**\n\n  * Visit Type: Outpatient \u2013 General Practice\n  * Date & Time: 2024-03-05 @ 10:15:22 (GMT+01:00)\n  * Clinician: Dr. P. Stevens, MD, MRCGP \n* **Ordering Provider:** Dr. P. Stevens\n* **Requesting Location:** GP Clinic \u2013 Room 3\n\n---\n\n#### 2. Trigger Details\n\n* **Trigger Rule:** Rule ID 4.2 \u2013 *ALT \u2265 1.5 \u00d7 ULN*\n* **Analyte:** Alanine Aminotransferase (ALT)\n* **Result:** 78 U/L (ULN: 40 U/L; 1.95 \u00d7 ULN) \n* **Associated LFTs at Time of Alert:** \n\n  * AST: 55 U/L (H, <35)\n  * ALP: 105 U/L (N, 30\u2013130)\n  * Bilirubin (Total): 12 \u03bcmol/L (N, <21)\n  * INR: 1.0 (N, 0.8\u20131.2)\n  * Platelets: 250 \u00d7 10\u2079/L (N, 150\u2013400)\n* **Pattern of Injury:** Hepatocellular (AST/ALT ratio \u2248 0.7; no cholestasis)\n* **Alert Level:** Level 2 \u2013 Non-Critical, Mandatory Acknowledgment within 72 hours\n* **Severity Banding (System):**\n\n  * ALT 1.5\u20133 \u00d7 ULN \u2192 *Moderate Elevation*\n  * Bilirubin normal, INR normal \u2192 *No acute liver failure criteria*\n\n---\n\n#### 3. Distribution & Delivery Log\n\n* **Primary Recipient:**\n\n  * Dr. P. Stevens (Responsible GP / LFT Ordering Clinician)\n* **Secondary Visibility:**\n\n  * GP Practice LFT Review Pool (Monitoring queue, \u201cGP-LFT-MONITOR\u201d)\n* **Delivery Channels:**\n\n  * Nervecentre mobile app push notification to Dr. Stevens\n  * Medilogik Inbox message (flagged \u2018LFT abnormal \u2013 review required\u2019)\n  * Alert icon added to Sarah Miller\u2019s digital chart (LFT flag)\n\n**Delivery Timeline:**\n\n1. **2024-03-05 10:17:02** \u2013 LFT panel verified in LIS; HL7 message received by Nervecentre.\n2. **2024-03-05 10:17:10** \u2013 Rule ID 4.2 fired (ALT 78 U/L \u2265 1.5 \u00d7 ULN).\n3. **2024-03-05 10:17:15** \u2013 Level 2 alert created and queued.\n4. **2024-03-05 10:17:20** \u2013 Push notification sent to Dr. Stevens\u2019 device and Medilogik Inbox.\n5. **2024-03-05 10:17:25** \u2013 Chart flag updated (amber LFT icon).\n\n---\n\n#### 4. Acknowledgment & Escalation Logic\n\n* **Acknowledgment Requirement:**\n\n  * Alert must be electronically acknowledged by the responsible clinician **within 72 hours** of creation.\n\n* **Current Status:**\n\n  * Acknowledgement: **Pending**\n  * Last System Check: 2024-03-05 18:00 \u2013 *No user interaction recorded.*\n\n* **Scheduled Reminders:**\n\n  * **+24 hours (2024-03-06 10:17)** \u2013 In-app reminder to Dr. Stevens (planned).\n  * **+48 hours (2024-03-07 10:17)** \u2013 Second reminder and addition to GP practice \u201cUnacknowledged LFT\u201d dashboard (planned).\n  * **+72 hours (2024-03-08 10:17)** \u2013 If still unacknowledged, auto-escalate to:\n\n    * GP Duty Doctor / Clinical Lead inbox\n    * Practice admin queue: \u201cFollow-up abnormal results \u2013 contact clinician\u201d.\n\n* **Escalation Rule:**\n\n  * Rule ID 7.1 \u2013 *Unacknowledged Level 2 lab alert >72 h \u2192 escalate to on-call / clinical lead.*\n\n---\n\n#### 5. Linked Tasks (Automatic)\n\n1. **Task ID:** NC-TASK-20240305-ALT-REVIEW\n\n   * **Title:** Review abnormal LFT (ALT 78 U/L) and document plan.\n   * **Owner:** Dr. P. Stevens\n   * **Priority:** Medium\n   * **Due Date/Time:** 2024-03-08 10:15 (72h from encounter)\n   * **Completion Status:** Open\n   * **Task Notes (Pre-populated):**\n\n     * \u201cALT 78 U/L (~1.95 \u00d7 ULN), hepatocellular pattern, no bilirubin or INR derangement. Consider MASLD, NSAID use, and DMARD candidacy (planned MTX). Document clinical correlation, repeat LFT interval, and DMARD decision.\u201d\n\n2. **Task ID:** NC-TASK-20240305-MASLD-COUNSEL\n\n   * **Title:** Confirm lifestyle counselling & weight-loss plan for suspected MASLD.\n   * **Owner:** GP Practice Nurse / Health Coach (Pool: \u2018MASLD-COACH\u2019)\n   * **Priority:** Low\n   * **Due Date/Time:** 2024-03-19 09:00\n   * **Status:** Open\n\n---\n\n#### 6. Safety & Governance Notes\n\n* **Protocol Reference:**\n\n  * Local GP LFT Policy v3.1 \u2013 \u201cAny ALT \u2265 1.5 \u00d7 ULN requires documented review and repeat LFT within 3\u20136 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).\u201d\n* **Clinical Risk Comment (System):**\n\n  * Flag added: \u201cPlanned DMARD (MTX) \u2013 ensure LFT trend and chronic liver disease screen BEFORE initiation.\u201d\n* **Audit Trail (Extract):**\n\n  * 2024-03-05 10:17 \u2013 Alert generated automatically (System).\n  * 2024-03-05 10:17 \u2013 Delivery confirmed to device \u2018STEVENS_GP_IPHONE\u2019.\n  * 2024-03-05 10:18 \u2013 Chart flag updated (System).\n  * *No user acknowledgment recorded yet.*\n\n",
                "dataSource": "Nervecentre",
                "highlights": [
                    {
                        "text": "Rule ID 4.2 \u2013 *ALT \u2265 1.5 \u00d7 ULN*",
                        "color": "yellow"
                    },
                    {
                        "text": "**Result:** 78 U/L (ULN: 40 U/L; 1.95 \u00d7 ULN)",
                        "color": "yellow"
                    },
                    {
                        "text": "AST: 55 U/L (H, <35)",
                        "color": "yellow"
                    },
                    {
                        "text": "Severity Banding (System):",
                        "color": "yellow"
                    },
                    {
                        "text": "ALT 1.5\u20133 \u00d7 ULN \u2192 *Moderate Elevation*",
                        "color": "yellow"
                    },
                    {
                        "text": "Local GP LFT Policy v3.1 \u2013 \u201cAny ALT \u2265 1.5 \u00d7 ULN requires documented review and repeat LFT within 3\u20136 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).\u201d",
                        "color": "yellow"
                    },
                    {
                        "text": "Planned DMARD (MTX) \u2013 ensure LFT trend and chronic liver disease screen BEFORE initiation.\u201d",
                        "color": "yellow"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-nervecentre-encounter-2",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "Nervecentre Encounter 2 - Critical MTX Alert with Highlights",
        "content": {
            "title": "Nervecentre - Encounter 2",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 5,
                "date": "2024-08-14",
                "visitType": "Outpatient",
                "provider": "Dr. R. Hall",
                "specialty": "Rheumatology",
                "rawText": "\n### **Nervecentre**\n\n**Module:** Laboratory Alerting & Medicines Safety\n**Event Type:** *Critical Medicine-Related LFT Alert \u2013 Methotrexate Patient*\n\n---\n\n## **1. Alert Event Summary**\n\n* **System Alert ID:** NC-LFT-20240814-003\n* **Patient:** Sarah Miller (MRN: SM43850603, DOB: 1981-06-03, 43F)\n* **Linked Encounter:**\n\n  * Visit Type: Outpatient \u2013 Rheumatology Review\n  * Date & Time: **2024-08-14 @ 14:32**\n  * Clinician: **Dr. R. Hall (Rheumatology Registrar)**\n* **Ordering Provider:** Dr. R. Hall\n* **Requesting Location:** Rheumatology Clinic \u2013 Room 5\n\n---\n\n## **2. Trigger Details**\n\n* **Trigger Rule:**\n\n  * **Rule 4.5 \u2013 ALT \u2265 3 \u00d7 ULN OR ALT \u2265 2 \u00d7 ULN in patients on hepatotoxic drugs (MTX).**\n\n* **Analyte Triggering Alert:**\n\n  * **ALT: 158 U/L** (ULN 40 U/L \u2192 **3.95 \u00d7 ULN**)\n\n* **Associated LFTs:**\n\n  * AST: 132 U/L (H)\n  * ALP: 118 U/L (N)\n  * Total Bilirubin: 17 \u03bcmol/L (N)\n  * Direct Bilirubin: 4 \u03bcmol/L (N)\n  * INR: 1.1 (N)\n  * Platelets: 238 \u00d7 10\u2079/L (N)\n\n* **Pattern of Injury:**\n\n  * **Hepatocellular**, ALT > AST > 3\u00d7 ULN, normal bilirubin\n\n* **Alert Level:** **Level 3 \u2013 *Critical hepatotoxicity (MTX patient)***\n\n* **Severity Banding:**\n\n  * MTX patient with ALT >3\u00d7 ULN \u2192 **\u201cImmediate clinical review required\u201d**\n\n* **Medication Linkage:**\n\n  * Methotrexate 15mg weekly (started ~12 weeks prior)\n  * Folic acid 5mg weekly\n\n---\n\n## **3. Distribution & Delivery Log**\n\n**Primary Recipients:**\n\n* Dr. R. Hall (Ordering clinician)\n* Rheumatology Consultant On-Call\n* GP (auto-copied for medicine safety review)\n\n**Secondary Recipients:**\n\n* Pharmacy / DMARD Safety Team (Queue: *DMARD-SAFETY-PRIORITY*)\n* Nervecentre Medicines Safety Dashboard\n\n**Delivery Channels:**\n\n* Nervecentre mobile push\n* Desktop inbox message\n* Email notification to Rheumatology duty mailbox (policy-mandated for Level 3 alerts)\n\n**Delivery Timeline:**\n\n1. **2024-08-14 14:33:10** \u2013 LFTs verified by lab\n2. **2024-08-14 14:33:16** \u2013 Rule 4.5 fired (ALT 158)\n3. **2024-08-14 14:33:20** \u2013 High-priority alert created\n4. **2024-08-14 14:33:25** \u2013 Push & desktop alerts sent to Rheumatology\n5. **2024-08-14 14:33:28** \u2013 Medicines Safety Dashboard updated (red flag)\n\nCurrent status: **Alert acknowledged by Dr. Hall at 14:41**\nEscalation aborted (acknowledged in time)\n\n---\n\n## **4. Acknowledgment & Escalation Logic**\n\n* **Acknowledgement Requirement:**\n\n  * Level 3 alerts require action **within 2 hours**.\n\n* **Acknowledgement Status:**\n\n  * **Acknowledged \u2013 Dr. Hall at 14:41**\n  * Comment: \u201cMTX held. Repeat LFTs in 48h. Arrange fibrosis screen & ultrasound.\u201d\n\n* **Escalation Path (not triggered):**\n\n  * Rheumatology Consultant (15 min delay)\n  * Duty Manager (if >2h unacknowledged)\n  * Pharmacy DMARD team (parallel escalation)\n\n---\n\n## **5. Linked Tasks (Automatic)**\n\n### **1. NC-TASK-20240814-MTX-HOLD**\n\n* **Title:** \u201cSuspend Methotrexate pending repeat LFTs\u201d\n* **Owner:** Dr. R. Hall\n* **Due:** Immediate\n* **Status:** **Completed (14:42)**\n* **Notes:** MTX paused; patient notified.\n\n---\n\n### **2. NC-TASK-20240814-LFT-REPEAT48H**\n\n* **Title:** \u201cRepeat LFT panel in 48 hours (MTX hepatotoxicity)\u201d\n* **Owner:** Phlebotomy Hub (*Priority*)\n* **Due:** 2024-08-16 @ 09:00\n* **Status:** Open\n\n---\n\n### **3. NC-TASK-20240814-CLD-SCREEN**\n\n* **Title:** \u201cNon-invasive liver disease screen (MASLD, viral, autoimmune)\u201d\n* **Owner:** GP Practice (Liver Screening Queue)\n* **Due:** 2024-08-21\n* **Status:** Open\n\n---\n\n## **6. Safety & Governance Notes**\n\n* **Policy Applied:**\n\n  * NHS DMARD Safety Monitoring \u2013 \u201cStop MTX if ALT > 3\u00d7 ULN.\u201d\n  * Local Hepatotoxicity Protocol v5.2\n\n* **System Safety Comments:**\n\n  * \u201cHigh probability of MTX-related transaminitis; ensure follow-up imaging & screen.\u201d\n  * \u201cNo synthetic dysfunction (INR normal). No bilirubin rise. No acute liver failure features.\u201d\n\n* **Audit Trail (Extract):**\n\n  * 14:33 \u2013 Alert created\n  * 14:33 \u2013 Notifications dispatched\n  * 14:41 \u2013 Acknowledged (Hall_R)\n  * 14:42 \u2013 Action documented: MTX held\n\n---\n\n## **7. Impact on Medicines Dashboard**\n\n* MTX moved to \u201c**Withheld \u2013 Abnormal LFT**\u201d\n* Next review set: **2024-08-16 (await repeat LFTs)**\n* Risk Score updated \u2192 **High**\n",
                "dataSource": "Nervecentre",
                "highlights": [
                    {
                        "text": "Rule 4.5 \u2013 ALT \u2265 3 \u00d7 ULN OR ALT \u2265 2 \u00d7 ULN in patients on hepatotoxic drugs (MTX).",
                        "color": "red"
                    },
                    {
                        "text": "**ALT: 158 U/L** (ULN 40 U/L \u2192 **3.95 \u00d7 ULN**)",
                        "color": "red"
                    },
                    {
                        "text": "AST: 132 U/L (H)",
                        "color": "red"
                    },
                    {
                        "text": "* **Alert Level:** **Level 3 \u2013 *Critical hepatotoxicity (MTX patient)***",
                        "color": "red"
                    },
                    {
                        "text": "MTX patient with ALT >3\u00d7 ULN \u2192 \u201cImmediate clinical review required\u201d",
                        "color": "red"
                    },
                    {
                        "text": "Methotrexate 15mg weekly (started ~12 weeks prior)",
                        "color": "yellow"
                    },
                    {
                        "text": "\u201cHigh probability of MTX-related transaminitis; ensure follow-up imaging & screen.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "\u201cNo synthetic dysfunction (INR normal). No bilirubin rise. No acute liver failure features.\u201d",
                        "color": "green"
                    },
                    {
                        "text": "MTX moved to \u201cWithheld \u2013 Abnormal LFT\u201d",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-nervecentre-encounter-3",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "Nervecentre Encounter 3 - Critical Inpatient Alert with Highlights",
        "content": {
            "title": "Nervecentre - Encounter 7",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 7,
                "date": "2024-09-02",
                "visitType": "Outpatient",
                "provider": "Dr. K. Hussain",
                "specialty": "AMU SHO",
                "rawText": "\n### **Nervecentre**\n\n**Module:** Laboratory Alerting, Inpatient Monitoring & Early Warning Scores\n**Event Type:** *Critical LFT Alert + AMU Deterioration Observation Trigger*\n**Location:** Acute Medical Unit (AMU) \u2013 Bed 12\n\n---\n\n## **1. Alert Event Summary**\n\n* **System Alert ID:** NC-LFT-20240902-009\n\n* **Patient:** **Sarah Miller** (MRN: SM43850603, 43F)\n\n* **Linked Encounter:**\n\n  * Admission Type: **Emergency \u2013 Medical**\n  * Date & Time: **2024-09-02 @ 18:22**\n  * Admitting Clinician: **Dr. K. Hussain (AMU SHO)**\n  * Responsible Consultant: **Dr. A. Bennett (Gastroenterology)**\n\n* **Clinical Presentation:**\n\n  * Nausea, reduced appetite, right upper quadrant discomfort\n  * Recent MTX cessation after abnormal LFTs\n  * Query **Methotrexate-related DILI vs MASLD flare**\n\n---\n\n## **2. Trigger Details \u2013 Critical LFT Alarm**\n\n### **Primary Trigger Rule:**\n\n* **Rule 4.7 \u2013 ALT \u2265 5 \u00d7 ULN OR significant rise since last test.**\n* **ALT: 242 U/L** (ULN 40 \u2192 **6.05 \u00d7 ULN**)\n* **AST: 198 U/L (H)**\n* **ALP: 130 U/L (upper-normal)**\n* \n* **Total Bilirubin: 26 \u03bcmol/L (mild elevation)**\n* **Direct Bilirubin: 8 \u03bcmol/L**\n* **INR: 1.2 (upper-normal, no synthetic failure)**\n* **Albumin: 39 g/L (normal)**\n* **Platelets: 212 \u00d7 10\u2079/L**\n\n### **Pattern of Injury:**\n\n* **Marked hepatocellular injury**\n* Mild bilirubin elevation (not cholestatic)\n* No acute liver failure criteria\n\n### **Severity Level:**\n\n* **Level 4 \u2013 Critical Alert (Inpatient)**\n* Requires **review within 30 minutes**\n\n### **Medication Linkage:**\n\n* MTX stopped 2 weeks ago\n* Patient on **prednisolone 10 mg** for RA flare\n* PRN paracetamol (flagged for dosing review)\n\n---\n\n## **3. Early Warning Score (NEWS2) Trigger**\n\n* **NEWS2 Score:** **4** (Yellow)\n\n  * HR 108\n  * RR 20\n  * Temp 37.8\u00b0C\n  * SpO\u2082 98% RA\n  * BP 122/78\n* Trigger: \u201c**Physiological change + abnormal blood tests \u2192 senior review required**\u201d\n\n### **Observation Alert ID:** NC-OBS-20240902-04\n\nDelivered simultaneously with the LFT alert.\n\n---\n\n## **4. Distribution & Delivery Log**\n\n**Primary Recipients:**\n\n* Dr. Hussain (Admitting SHO)\n* AMU Registrar (Dr. Maxwell)\n* Gastroenterology On-Call Team\n* Medicines Safety Team (due to previous MTX exposure)\n\n**Secondary Recipients:**\n\n* AMU Nurse in Charge\n* EWS (NEWS2) Monitoring Dashboard\n* Liver Pathway Tracker\n\n### **Delivery Timeline**\n\n1. **18:24:50** \u2013 LFTs verified\n2. **18:24:55** \u2013 Rule 4.7 fired (ALT 242)\n3. **18:25:00** \u2013 Critical alert sent (Level 4)\n4. **18:25:05** \u2013 NEWS2 trigger elevated to \u201cUrgent Review\u201d\n5. **18:25:10** \u2013 On-call Gastroenterology bleeped automatically\n6. **18:27:14** \u2013 Acknowledged by **Dr. Hussain (AMU SHO)**\n7. **18:33:22** \u2013 Registrar review documented (Maxwell_J)\n\n---\n\n## **5. Acknowledgment & Escalation Logic**\n\n* **Required Acknowledgement:** Within **30 min**\n* **Status:**\n\n  * **Acknowledged \u2013 On time (Dr. Hussain @ 18:27)**\n\n### **Escalation process (auto-triggered but closed):**\n\n* **Stage 1 \u2013 SHO (5 min)** \u2192 Completed\n* **Stage 2 \u2013 Registrar (15 min)** \u2192 Completed\n* **Stage 3 \u2013 Gastro Consultant (manual if worsening)** \u2192 Not required\n\n### **Registrar Safety Note:**\n\n\u201cLikely MTX-related hepatocellular injury, improving bilirubin. Keep NBM for abdominal US, order hepatitis serologies, and trend LFTs q12h.\u201d\n\n---\n\n## **6. Linked Inpatient Tasks (Automatic)**\n\n### **1. NC-TASK-20240902-LFTQ12**\n\n* **Title:** \u201cRepeat LFT + INR every 12 hours\u201d\n* **Owner:** AMU Nursing & Phlebotomy\n* **Due:** First repeat at **06:00 (03-Sept)**\n* **Status:** Open\n\n---\n\n### **2. NC-TASK-20240902-US-LIVER**\n\n* **Title:** \u201cArrange urgent liver ultrasound\u201d\n* **Owner:** Radiology \u2013 Priority Queue\n* **Due:** Within 24h\n* **Status:** Open\n* **Notes:** NBM from midnight.\n\n---\n\n### **3. NC-TASK-20240902-VIRAL-AUTOIMMUNE-SCREEN**\n\n* **Title:** \u201cComplete full non-invasive liver screen (viral, autoimmune, metabolic)\u201d\n* **Owner:** AMU SHO\n* **Due:** 2024-09-03 @ 14:00\n* **Status:** Open\n* **Pre-populated Notes:**\n\n  * HBV surface antigen\n  * HCV Ab\n  * ANA, ASMA, AMA\n  * Ferritin, transferrin saturation\n  * Coeliac serology\n\n---\n\n### **4. NC-TASK-20240902-DILI-REVIEW**\n\n* **Title:** \u201cConsultant Gastro review for suspected DILI\u201d\n* **Owner:** Dr. Bennett\n* **Due:** Same day (post-ward round)\n* **Status:** Pending Consultant signature\n\n---\n\n## **7. Safety & Governance Notes**\n\n* **Policies Applied:**\n\n  * Acute Liver Injury Protocol v4.0\n  * DMARD Monitoring (MTX section)\n  * NEWS2 Escalation Framework\n  * Risk of DILI \u2013 high if ALT > 5\u00d7 ULN\n\n* **System Warnings:**\n\n  * \u201cRecent MTX exposure \u2013 evaluate for DILI.\u201d\n  * \u201cTrend LFTs closely; risk of progression without synthetic failure yet.\u201d\n  * \u201cInvestigate MASLD overlap given BMI and T2DM.\u201d\n\n* **Audit Trail (Extract):**\n\n  * 18:25 \u2013 Alert created\n  * 18:25 \u2013 Gastro team notified\n  * 18:27 \u2013 SHO acknowledgment\n  * 18:33 \u2013 Registrar review documented\n  * 18:34 \u2013 LFT-trend monitoring scheduled\n\n---\n\n## **8. Inpatient Liver Monitoring Dashboard Update**\n\n* **Status:** HIGH RISK \u2013 Hepatocellular injury\n* **Next data refresh:** 12-hourly\n* **Outstanding items:**\n\n  * Ultrasound\n  * Viral/autoimmune screen\n  * Consultant review\n  * LFT trend check\n",
                "dataSource": "Nervecentre",
                "highlights": [
                    {
                        "text": "ALT: 242 U/L (ULN 40 \u2192 6.05 \u00d7 ULN)",
                        "color": "red"
                    },
                    {
                        "text": "AST: 198 U/L (H)",
                        "color": "red"
                    },
                    {
                        "text": "Total Bilirubin: 26 \u03bcmol/L (mild elevation)",
                        "color": "yellow"
                    },
                    {
                        "text": "Marked hepatocellular injury",
                        "color": "red"
                    },
                    {
                        "text": "Level 4 \u2013 Critical Alert (Inpatient)",
                        "color": "red"
                    },
                    {
                        "text": "Risk of DILI \u2013 high if ALT > 5\u00d7 ULN",
                        "color": "red"
                    },
                    {
                        "text": "Recent MTX exposure \u2013 evaluate for DILI.",
                        "color": "red"
                    },
                    {
                        "text": "Trend LFTs closely; risk of progression without synthetic failure yet.",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "iframe-item-easl-interface",
        "type": "iframe",
        "title": "EASL Web Interface",
        "iframeUrl": "https://easl-board.vercel.app/",
        "conversationHistory": []
    },
    {
        "id": "raw-ice-orders-encounter-2",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "ICE Pre-DMARD Screening Orders with Highlights",
        "content": {
            "title": "ICE - Dr. P. Stevens",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 2,
                "date": "2024-04-01",
                "visitType": "Routine",
                "provider": "Dr. P. Stevens",
                "specialty": "Unknown",
                "rawText": "\n**ICE**\n**Order Set:** *Comprehensive Chronic Hepatitis & Hepatic Fitness Screening (Pre-DMARD Initiation)*\n**Ordering Clinician:** Dr. P. Stevens, MD, MRCGP\n**Date:** 2024-04-01\n**Location:** GP Outpatient Clinic\n**Indication:** *Abnormal ALT (78 U/L) and pre-Methotrexate screening*\n**Urgency:** Routine (Non-urgent, but required before treatment)\n**Associated Diagnosis Code:** SNOMED CT \u2013 *Rheumatoid arthritis (69896004)* + *Transaminitis (197315008)*\n\n---\n\n## **1. Viral Hepatitis Serology Panel**\n\n**Tests Ordered:**\n\n* HBsAg \u2013 Hepatitis B Surface Antigen\n* Anti-HBc Total \u2013 Hepatitis B Core Antibody\n* Anti-HCV \u2013 Hepatitis C Antibody\n* HEV IgG \u2013 Hepatitis E Antibody (IgG)\n\n**Priority:** Routine\n**Turnaround:** 48\u201372 hours\n**Specimen:** Serum (Gold top)\n\n**Extended Laboratory Note for Technologists:**\n\u201cPre-DMARD safety testing. Patient requires clearance prior to potential MTX initiation.\nPlease ensure reflex testing for HBV DNA if:\n\n* HBsAg positive OR\n* Isolated anti-HBc positivity.\n  This result determines antiviral prophylaxis requirements before DMARDs.\u201d\n\n**Clinical Rationale:**\n\u201cFull viral exclusion is mandatory. Even occult HBV could lead to reactivation under MTX. HCV/HEV exclusion required to avoid missed chronic inflammation.\u201d\n\n---\n\n## **2. Autoimmune Hepatitis Screening Panel**\n\n**Tests Ordered:**\n\n* ANA with reflex titre\n* ASMA (Anti-Smooth Muscle Antibody)\n* LKM-1 (Liver-Kidney Microsomal Antibody)\n* Total IgG\n\n**Priority:** Routine\n**Turnaround:** 5\u20137 days\n**Specimen:** Serum\n\n**Extended Note:**\n\u201cIf ANA positive, perform reflex titre and pattern ID.\nIf IgG > upper limit, flag result for consultant pathologist review.\u201d\n\n**Clinical Rationale:**\n\u201cRule out autoimmune hepatitis. Active AIH is an absolute contraindication to starting MTX. MTX may worsen hepatic autoimmune inflammation.\u201d\n\n---\n\n## **3. Metabolic Liver Screen**\n\n**Tests Ordered:**\n\n* Serum Ferritin\n* TIBC (Total Iron-Binding Capacity)\n* Transferrin Saturation (%)\n* Alpha-1 Antitrypsin Level\n\n**Priority:** Routine\n**Turnaround:** 48 hours\n**Specimen:** Serum\n\n**Extended Note:**\n\u201cFerritin >300 or transferrin saturation >45% should reflex to HFE genetic typing.\nLow A1AT level should reflex to phenotype typing if available.\u201d\n\n**Clinical Rationale:**\n\u201cExclude haemochromatosis and A1AT deficiency\u2014both amplify DILI risk and are critical to identify before MTX.\u201d\n\n---\n\n## **4. Repeat Liver Function Panel (Scheduled)**\n\n**Tests Ordered:**\n\n* ALT\n* AST\n* ALP\n*  Bilirubin (Total & Direct)\n* INR\n* Albumin\n* Platelets (FBC add-on)\n* R-Factor auto-calculation\n\n**Priority:** Deferred / Scheduled for 4 weeks\n**Target Date:** 2024-05-01\n**Turnaround:** Same day\n**Specimen:** Serum + Coag tube\n\n**Extended Note:**\n\u201cTrend assessment required. If ALT remains above 1.5\u00d7 ULN, do not proceed with MTX.\nIf ALT normalizes, clear for low-dose MTX initiation.\nICE to generate automatic reminder 3 days before due date.\u201d\n\n**Clinical Rationale:**\n\u201cTo confirm normalization of hepatic inflammation and determine hepatic fitness prior to hepatotoxic DMARD therapy.\u201d\n\n---\n\n## **ICE System Flags Applied**\n\n* **Safety Flag:** \u201cMTX Pre-Check Required \u2013 Do Not Initiate Until Results Reviewed.\u201d\n* **Auto-Alert:** Notify ordering clinician if results show:\n\n  * HBsAg positive\n  * ALT > 2\u00d7 ULN\n  * IgG significantly elevated\n  * Positive autoimmune markers\n* **Patient Status Flag:** \u201cRecurrent MASLD flare \u2013 monitor trends.\u201d\n\n---\n\n## **Specimen Collection Instructions**\n\n* Fasting NOT required\n* Advise patient to avoid NSAIDs 48h prior to blood draw\n* Document alcohol intake in the last 72 hours\n* Ensure same-day processing for INR\n\n---\n",
                "dataSource": "ICE",
                "highlights": [
                    {
                        "text": "Abnormal ALT (78 U/L) and pre-Methotrexate screening",
                        "color": "yellow"
                    },
                    {
                        "text": "HBsAg \u2013 Hepatitis B Surface Antigen",
                        "color": "green"
                    },
                    {
                        "text": "Anti-HBc Total \u2013 Hepatitis B Core Antibody",
                        "color": "green"
                    },
                    {
                        "text": "Anti-HCV \u2013 Hepatitis C Antibody",
                        "color": "green"
                    },
                    {
                        "text": "HEV IgG \u2013 Hepatitis E Antibody (IgG)",
                        "color": "green"
                    },
                    {
                        "text": "HBV DNA if: HBsAg positive OR Isolated anti-HBc positivity.",
                        "color": "red"
                    },
                    {
                        "text": "Even occult HBV could lead to reactivation under MTX.",
                        "color": "red"
                    },
                    {
                        "text": "Rule out autoimmune hepatitis.",
                        "color": "red"
                    },
                    {
                        "text": "Active AIH is an absolute contraindication to starting MTX.",
                        "color": "red"
                    },
                    {
                        "text": "MTX may worsen hepatic autoimmune inflammation.",
                        "color": "red"
                    },
                    {
                        "text": "Exclude haemochromatosis and A1AT deficiency\u2014both amplify DILI risk and are critical to identify before MTX.",
                        "color": "yellow"
                    },
                    {
                        "text": "If ALT remains above 1.5\u00d7 ULN, do not proceed with MTX.",
                        "color": "yellow"
                    },
                    {
                        "text": "To confirm normalization of hepatic inflammation and determine hepatic fitness prior to hepatotoxic DMARD therapy.",
                        "color": "yellow"
                    },
                    {
                        "text": "HBsAg positive",
                        "color": "red"
                    },
                    {
                        "text": "ALT > 2\u00d7 ULN",
                        "color": "red"
                    },
                    {
                        "text": "Positive autoimmune markers",
                        "color": "red"
                    },
                    {
                        "text": "Recurrent MASLD flare \u2013 monitor trends.",
                        "color": "yellow"
                    },
                    {
                        "text": "Advise patient to avoid NSAIDs 48h prior to blood draw",
                        "color": "yellow"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-ice-orders-encounter-6",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "ICE Acute DILI Emergency Orders with Highlights",
        "content": {
            "title": "ICE - Dr. P. Stevens",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 6,
                "date": "2024-08-12",
                "visitType": "Routine",
                "provider": "Dr. P. Stevens",
                "specialty": "Unknown",
                "rawText": "\n**ICE**\n**Order Set:** *Acute Liver Injury Diagnostic & Management Pathway (ED Rapid Evaluation Protocol)*\n**Ordering Clinician:** Dr. P. Stevens\n**Date:** 2024-08-12\n**Location:** ED \u2013 Rapid Assessment Bay\n**Indication:** *Severe Acute Hepatocellular DILI with bilirubin >100 \u03bcmol/L, ALT 490 U/L*\n**Priority:** **STAT / Emergency**\n**Linked Diagnosis Codes:**\n\n* *Drug-Induced Liver Injury (DILI) \u2014 SNOMED CT: 240517000*\n* *Acute Jaundice \u2014 43959009*\n* *Cholestasis \u2014 14140009*\n\n---\n\n# **1. Acute Liver Function & Synthetic Function Panel (STAT)**\n\n**Tests Ordered:**\n\n* ALT\n* AST\n* ALP\n*  Total Bilirubin\n* Direct (Conjugated) Bilirubin\n* INR / PT\n* APTT\n* Albumin\n* Platelet count (FBC)\n* R-Factor auto-calculation\n* MELD components\n\n**Specimen:** Serum (Gold top) + Coagulation tube (Blue top)\n**Turnaround:** **1 hour**\n**Laboratory Notes:**\n\u201cPrioritize processing\u2014patient meets criteria for severe DILI.\nIf INR \u2265 1.5, notify Hepatology Consultant immediately and escalate to level II care.\u201d\n\n**Clinical Rationale:**\n\u201cTo quantify severity of hepatocellular injury, identify synthetic dysfunction early, and determine risk of progression to acute liver failure.\u201d\n\n---\n\n# **2. Complete ED Acute Hepatitis Panel (STAT)**\n\n**Tests Ordered:**\n\n* HBsAg\n* Anti-HBc IgM\n* HBV DNA (reflex if HBsAg positive OR if IgM equivocal)\n* HAV IgM\n* HCV Ab with reflex PCR\n* HEV IgM & IgG\n\n**Specimen:** Serum\n**Turnaround:** 24\u201348h for serology, PCR reflex automatically flagged\n\n**Extended Notes to Laboratory:**\n\u201cPatient presents with DILI picture but high bilirubin requires exclusion of superimposed acute viral hepatitis.\nReflex HBV DNA and HCV RNA without waiting for GP approval.\u201d\n\n**Clinical Rationale:**\n\u201cTo rule out acute viral hepatitis coexisting with drug-induced hepatocellular injury.\u201d\n\n---\n\n# **3. Autoimmune Hepatitis Acute Panel (Urgent)**\n\n**Tests Ordered:**\n\n* ANA\n* ASMA\n* LKM-1\n* IgG\n* AMA (Anti-Mitochondrial Antibody)\n\n**Priority:** Urgent\n**Specimen:** Serum\n**Turnaround:** 48\u201372 hours\n\n**Extended Notes:**\n\u201cIf IgG > ULN or ANA positive, flag as \u2018Potential AIH\u2019 and notify Hepatology.\u201d\n\n---\n\n# **4. Metabolic Liver Injury Screen (Urgent)**\n\n**Tests Ordered:**\n\n* Ferritin\n* Transferrin saturation\n* TIBC\n* Alpha-1-antitrypsin\n* Ceruloplasmin (to exclude Wilson\u2019s disease in <45 y/o)\n\n**Specimen:** Serum\n\n**Clinical Rationale:**\n\u201cTo identify possible metabolic or genetic cofactors worsening acute DILI.\u201d\n\n---\n\n# **5. Abdominal Ultrasound (USG Abdomen Upper) \u2013 STAT (1 hour)**\n\n**Order:** USG Abdomen Complete\n**Target time:** 1 hour\n**Indication:** *Bilirubin 110 \u03bcmol/L \u2014 exclude obstruction, gallstones, duct dilation, hepatic lesions, biliary obstruction.*\n\n**Radiology Notes:**\n\u201cHigh suspicion for hepatocellular injury, but bilirubin >100 requires urgent exclusion of obstructive pathology.\nIf bile duct dilation >8 mm \u2192 escalate to MRCP.\u201d\n\n---\n\n# **6. MRCP (Conditional Reflex Order)**\n\n**Criteria to trigger reflex:**\n\n* Ultrasound suggests ductal dilation OR\n* Suspicion of choledocholithiasis OR\n* Cholestasis disproportionate to transaminases\n\n**Priority:** Urgent\n**Clinical Rationale:**\n\u201cTo confirm or exclude mechanical obstruction as cause of intense jaundice.\u201d\n\n---\n\n# **7. NAC IV Infusion \u2014 Emergency Order**\n\n**Order:** N-acetylcysteine 3-bag infusion protocol\n**Dose:** Weight: 85 kg\n**Bag 1:** 150 mg/kg over 1 hour\n**Bag 2:** 50 mg/kg over 4 hours\n**Bag 3:** 100 mg/kg over 16 hours\n\n**Pharmacy Notes:**\n\u201cThis is *non-paracetamol DILI*, but NAC indicated due to ALT >1000/12\u00d7 ULN risk category.\nStart immediately\u2014do not delay for lab confirmation.\u201d\n\n**Clinical Rationale:**\n\u201cNAC improves outcomes in non-paracetamol DILI by reducing oxidative stress.\u201d\n\n---\n\n# **8. Hepatology Consult \u2013 STAT**\n\n**Consult level:** Consultant Hepatologist\n**Criteria:**\n\n* Bilirubin >100\n* ALT >10\u00d7 ULN\n* AST >350\n* Jaundice + severe nausea\n* MASLD background\n\n**Clinical Rationale:**\n\u201cRequires specialist oversight and risk stratification for acute liver failure.\u201d\n\n---\n\n# **9. Inpatient Admission Order \u2013 Hepatology Ward**\n\n**Level:** Urgent\n**Destination:** Hepatology Ward (High Monitoring Pathway)\n**Reason:**\n\n* Severe DILI\n* Need for neuro status monitoring q4h\n* INR monitoring daily\n* Ongoing NAC therapy\n\n---\n\n# **10. ICE System Safety Flags Applied**\n\n* **Red Flag:** \u201cACUTE SEVERE DILI \u2014 DO NOT DISCHARGE FROM ED.\u201d\n* **Auto-alert:**\n\n  * If INR \u2265 1.5 \u2192 escalate to Consultant + Critical Care\n  * If bilirubin rises by >25% in 12 hours \u2192 notify Hepatology\n* **Medication Stop Order:**\n\n  * \u201cMethotrexate marked as PERMANENTLY CONTRAINDICATED\u201d\n* **Trend Reminder:**\n\n  * New LFT panel automatically scheduled at **+12 hours**\n\n---\n\n# **11. Specimen Collection Instructions**\n\n* Collect **two sets** of serum tubes due to high probability of add-on testing\n* Coagulation tube must be processed within 30 minutes\n* Mark all specimens \u201cSTAT \u2014 ACUTE LIVER INJURY\u201d\n* Ensure patient receives IV access prior to NAC initiation\n\n---\n",
                "dataSource": "ICE",
                "highlights": [
                    {
                        "text": "Severe Acute Hepatocellular DILI with bilirubin >100 \u03bcmol/L, ALT 490 U/L",
                        "color": "red"
                    },
                    {
                        "text": "Drug-Induced Liver Injury (DILI) \u2014 SNOMED CT: 240517000",
                        "color": "red"
                    },
                    {
                        "text": "Acute Jaundice \u2014 43959009",
                        "color": "red"
                    },
                    {
                        "text": "Cholestasis \u2014 14140009",
                        "color": "red"
                    },
                    {
                        "text": "\u201cPrioritize processing\u2014patient meets criteria for severe DILI.",
                        "color": "red"
                    },
                    {
                        "text": "\u201cTo quantify severity of hepatocellular injury, identify synthetic dysfunction early, and determine risk of progression to acute liver failure.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "\u201cPatient presents with DILI picture but high bilirubin requires exclusion of superimposed acute viral hepatitis.",
                        "color": "red"
                    },
                    {
                        "text": "\u201cTo rule out acute viral hepatitis coexisting with drug-induced hepatocellular injury.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "\u201cIf IgG > ULN or ANA positive, flag as \u2018Potential AIH\u2019 and notify Hepatology.\u201d",
                        "color": "yellow"
                    },
                    {
                        "text": "\u201cTo identify possible metabolic or genetic cofactors worsening acute DILI.\u201d",
                        "color": "yellow"
                    },
                    {
                        "text": "Bilirubin 110 \u03bcmol/L \u2014 exclude obstruction, gallstones, duct dilation, hepatic lesions, biliary obstruction.",
                        "color": "red"
                    },
                    {
                        "text": "\u201cHigh suspicion for hepatocellular injury, but bilirubin >100 requires urgent exclusion of obstructive pathology.",
                        "color": "red"
                    },
                    {
                        "text": "\u201cTo confirm or exclude mechanical obstruction as cause of intense jaundice.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "This is *non-paracetamol DILI*, but NAC indicated due to ALT >1000/12\u00d7 ULN risk category.",
                        "color": "red"
                    },
                    {
                        "text": "NAC improves outcomes in non-paracetamol DILI by reducing oxidative stress.\u201d",
                        "color": "yellow"
                    },
                    {
                        "text": "Bilirubin >100",
                        "color": "red"
                    },
                    {
                        "text": "ALT >10\u00d7 ULN",
                        "color": "red"
                    },
                    {
                        "text": "Jaundice + severe nausea",
                        "color": "red"
                    },
                    {
                        "text": "\u201cRequires specialist oversight and risk stratification for acute liver failure.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "Severe DILI",
                        "color": "red"
                    },
                    {
                        "text": "Need for neuro status monitoring q4h",
                        "color": "red"
                    },
                    {
                        "text": "Red Flag: \u201cACUTE SEVERE DILI \u2014 DO NOT DISCHARGE FROM ED.\u201d",
                        "color": "red"
                    },
                    {
                        "text": "Auto-alert:",
                        "color": "red"
                    },
                    {
                        "text": "If INR \u2265 1.5 \u2192 escalate to Consultant + Critical Care",
                        "color": "red"
                    },
                    {
                        "text": "If bilirubin rises by >25% in 12 hours \u2192 notify Hepatology",
                        "color": "red"
                    },
                    {
                        "text": "Methotrexate marked as PERMANENTLY CONTRAINDICATED",
                        "color": "red"
                    },
                    {
                        "text": "New LFT panel automatically scheduled at +12 hours",
                        "color": "yellow"
                    },
                    {
                        "text": "Mark all specimens \u201cSTAT \u2014 ACUTE LIVER INJURY\u201d",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-vueexplore-ultrasound-6",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "VueExplore Ultrasound - Encounter 6 with Highlights",
        "content": {
            "title": "VueExplore - Ultrasound 6",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 6,
                "date": "2024-08-12",
                "visitType": "Radiology",
                "provider": "Dr. P. Stevens",
                "specialty": "MRCGP",
                "rawText": "**VueExplore**\n**Study Type:** *Ultrasound Abdomen \u2013 Emergency / STAT*\n**Accession Number:** **USG-240812-001**\n**Exam Date & Time:** **2024-08-12 @ 15:02**\n**Referring Clinician:** Dr. P. Stevens\n**Location:** Emergency Department \u2192 Radiology Acute Imaging Bay\n**Clinical Indication:**\n\n* Severe acute jaundice\n* ALT 490 U/L, AST 350 U/L\n* Bilirubin 110 \u03bcmol/L\n* Suspected **Acute Drug-Induced Liver Injury**\n* Need to rule out **obstructive cholestasis** or **biliary obstruction**\n\n---\n\n# **1. Acquisition Details**\n\n* **Modality:** Ultrasound (US) \u2013 B-mode + Colour Doppler\n* **Scanner:** Philips EPIQ Elite\n* **Operator:** Senior Sonographer \u2013 S. Patel\n* **Views Obtained:**\n\n  * Longitudinal and transverse liver views\n  * CBD (common bile duct) measurement\n  * Gallbladder (multiple planes)\n  * Right kidney\n  * Pancreatic head region\n  * Portal vein Doppler waveform\n* **Exam Quality:** Good; patient tolerated exam despite nausea.\n\n---\n\n# **2. Detailed Radiology Report**\n\n### **Liver**\n\n* Liver size: Normal range\n* Parenchymal echotexture: Mildly increased, consistent with **steatosis / MASLD**\n* No focal hepatic lesions\n* No intrahepatic biliary ductal dilatation\n* No free fluid\n* No signs of hepatic congestion\n\n### **Gallbladder**\n\n* Normal wall thickness\n* No gallstones seen\n* No pericholecystic fluid\n* Sonographic Murphy\u2019s sign: **Negative**\n\n### **Biliary Tree**\n\n* **Common bile duct (CBD): 5.1 mm (normal)**\n* No evidence of obstruction\n* No choledocholithiasis\n* Normal tapering at the pancreatic head\n\n### **Pancreas**\n\n* Head and proximal body visualised; no mass or dilation of pancreatic duct\n* No evidence of obstructive tumour causing cholestasis\n\n### **Portal Vein (Doppler)**\n\n* Normal hepatopetal flow\n* Velocity within normal physiological range\n* No portal vein thrombosis or flow abnormality\n\n### **Spleen**\n\n* Normal size, no splenomegaly (supports absence of portal hypertension)\n\n### **Kidneys**\n\n* Right kidney normal, no hydronephrosis\n* Left kidney partially visualised; normal contour\n\n---\n\n# **3. Radiologist Impression (Final Report)**\n\n**Reported by:** Dr. L. Andrews, Consultant Radiologist\n**Report Time:** 2024-08-12 @ 15:25\n\n**Impression:**\n\n1. **No sonographic evidence of biliary obstruction** \u2013 CBD normal, no stones, and no intrahepatic duct dilation.\n2. Liver shows **mild steatosis**, compatible with known MASLD.\n3. No structural cause identified for the acute rise in bilirubin.\n4. Findings support a **hepatocellular process**, consistent with **Drug-Induced Liver Injury (DILI)** rather than obstructive jaundice.\n5. No free fluid, no focal liver lesions, and no signs of acute cholecystitis.\n\n---\n\n# **4. VueExplore System Flags**\n\n* **Flag Applied:** *\u201cNo mechanical obstruction detected \u2013 hepatocellular injury pathway confirmed.\u201d*\n* **Auto-Trigger:**\n\n  * \u201cMRCP not indicated unless bilirubin rises beyond 150 \u03bcmol/L OR clinical suspicion changes.\u201d\n  * Notify Hepatology Consultant of completed imaging.\n* **Priority Update:** Imaging urgency downgraded from \u201cSTAT\u201d to \u201cRoutine Monitoring\u201d after non-obstructive findings.\n\n---\n\n# **5. Recommendations (Auto-generated VueExplore decision block)**\n\n* Continue with **NAC protocol** for severe hepatocellular injury.\n* Maintain **Hepatology admission** for close monitoring.\n* Repeat ultrasound only if:\n\n  * bilirubin increases\n  * cholestasis worsens\n  * new abdominal pain develops\n* Consider MR elastography or Fibroscan post-recovery (3\u20136 months).\n\n---\n\n# **6. Audit & Workflow Log**\n\n* 14:58 \u2014 ED order placed\n* 15:02 \u2014 Patient arrived in ultrasound bay\n* 15:03 \u2014 First image acquired\n* 15:25 \u2014 Report finalized by Consultant Radiologist\n* 15:27 \u2014 Report auto-delivered to:\n\n  * ED Clinician Inbox\n  * Hepatology On-Call Team\n  * Nervecentre alert module\n* 15:28 \u2014 Care plan updated to: \u201cProceed with hepatocellular DILI pathway\u201d\n",
                "dataSource": "Viper",
                "highlights": [
                    {
                        "text": "Severe acute jaundice",
                        "color": "red"
                    },
                    {
                        "text": "ALT 490 U/L, AST 350 U/L",
                        "color": "red"
                    },
                    {
                        "text": "Bilirubin 110 \u03bcmol/L",
                        "color": "red"
                    },
                    {
                        "text": "Suspected **Acute Drug-Induced Liver Injury**",
                        "color": "red"
                    },
                    {
                        "text": "Liver shows **mild steatosis**, compatible with known MASLD.",
                        "color": "yellow"
                    },
                    {
                        "text": "Findings support a **hepatocellular process**, consistent with **Drug-Induced Liver Injury (DILI)** rather than obstructive jaundice.",
                        "color": "red"
                    },
                    {
                        "text": "Continue with **NAC protocol** for severe hepatocellular injury.",
                        "color": "red"
                    },
                    {
                        "text": "Maintain **Hepatology admission** for close monitoring.",
                        "color": "red"
                    },
                    {
                        "text": "Care plan updated to: \u201cProceed with hepatocellular DILI pathway\u201d",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-bighand-dictation-stevens-2024",
        "type": "component",
        "componentType": "RawClinicalNote",
        "description": "BigHand Dictation - Dr. Stevens Detailed Clinical Commentary with Highlights",
        "content": {
            "title": "BigHand - Dr. P. Stevens",
            "component": "RawClinicalNote",
            "props": {
                "encounterNumber": 2,
                "date": "2024-04-01",
                "visitType": "Outpatient",
                "provider": "Dr. P. Stevens",
                "specialty": "Unknown",
                "rawText": "\n# **Expanded BigHand Dictation **\n\n**Transcript ID:** GP_SM_0401_WorkupAndCaution_Full (Expanded Version)\n**Dictated by:** Dr. P. Stevens, MD, MRCGP\n**Length:** ~4 minutes, 45 seconds\n\n---\n\n### **Text (Full Dictation and Clinical Commentary)**\n\n\"Dictation for Sarah Miller, date of birth 3rd June 1981, reviewed today in clinic for follow-up of her abnormal liver function tests and to discuss suitability for commencing Methotrexate for rheumatoid arthritis.\n\nThis was a longer consultation than standard, as the focus today was not only on reviewing numbers but explaining the meaning behind them and ensuring the patient understands the implications for future treatment choices. Sarah presented well, in no acute distress, but her blood tests from last month remain concerning, specifically an ALT of 78 U/L, which is nearly twice the upper limit of normal. The pattern continues to suggest a hepatocellular injury, consistent with the background suspicion of metabolic dysfunction-associated steatotic liver disease MASLD and the long-standing metabolic risk factors we documented previously, including type 2 diabetes, suboptimal glycaemic control, and moderate alcohol intake.\n\nI spent a large portion of this appointment clarifying what this raised ALT means in the context of planning Methotrexate therapy. Methotrexate is a highly effective DMARD, but one with well-established hepatotoxic potential. Its safe use depends entirely on starting it in a liver that is already stable, ideally with completely normal aminotransferases. Even mild instability in LFTs increases risk, but when the baseline ALT is already elevated, as in Sarah\u00e2\u20ac\u2122s case, the risk of clinically meaningful injury potentially even severe DILI rises significantly.\n\nI explained in detail the concept of **synergistic hepatotoxicity**   that is, the combined effect of two stressors on the liver producing significantly more damage than either would alone. In her scenario, the \u00e2\u20ac\u02dcfirst hit\u00e2\u20ac\u2122 is MASLD, which causes chronic low-grade hepatic inflammation. Adding Methotrexate, which itself generates oxidative stress and can create hepatic stellate activation, easily tips the balance into injury. The risk is not theoretical: the evidence base clearly shows that patients with MASLD are more vulnerable to Methotrexate-induced hepatic fibrosis and steatohepatitis.\n\nBecause of this, I emphasised to Sarah that we cannot safely proceed with Methotrexate until we definitively exclude other possible chronic liver diseases that would compound the risk further. I explained that viral hepatitis particularly hepatitis B core antibody positivity would fundamentally change monitoring requirements and contraindications. Autoimmune hepatitis must also be excluded because Methotrexate is strongly contraindicated in active AIH, as it can both exacerbate hepatic inflammation and mask clinical symptoms until severe injury has occurred. We therefore agreed to perform the most comprehensive first-line hepatitis and autoimmune screening panel.\n\nI walked Sarah through each test ordered today:\n\u00e2\u20ac\u00a2 Viral serology   HBsAg, hepatitis B core total antibody, hepatitis C antibody, and HEV IgG. I explained that even if surface antigen is negative, a positive core antibody would require modification of future DMARD regimens, and possible prophylaxis, depending on risk.\n\u00e2\u20ac\u00a2 Autoimmune screen   ANA, ASMA, LKM-1 and total IgG, which allow us to reliably detect autoimmune hepatitis patterns.\n\u00e2\u20ac\u00a2 Metabolic screen   ferritin, transferrin saturation and alpha-1-antitrypsin levels, to exclude haemochromatosis and AAT deficiency. Both of these conditions increase susceptibility to DILI and accelerate fibrosis if Methotrexate is used.\n\u00e2\u20ac\u00a2 And a repeat full LFT panel in four weeks, which will help differentiate between a stable chronic mild MASLD pattern versus a dynamic or inflammatory process.\n\nI made it clear to Sarah that if this workup shows viral or autoimmune pathology, Methotrexate would be absolutely contraindicated and we would need to pursue alternative RA management, likely hydroxychloroquine or a biologic agent depending on rheumatology input. If the panel is negative, but ALT remains raised, we will still need to be extremely cautious, as underlying steatohepatitis, even if non-viral and non-autoimmune, carries higher risk.\n\nSarah was understandably disappointed as she has been hoping for Methotrexate to improve her arthritis symptoms. However, by the end of the discussion she demonstrated good insight into the reasons for delaying treatment. She agreed that patient safety must take precedence, and she verbalised understanding that rushing into therapy could expose her to serious complications.\n\nI also advised Sarah strongly to avoid all NSAID use for now particularly ibuprofen which she normally takes up to five times a week. NSAIDs do carry their own hepatotoxic potential, and we must avoid any additional hepatic irritants until her LFTs settle and the screening is complete.\n\nFinally, I confirmed that she should contact the surgery promptly if she develops any new symptoms such as nausea, jaundice, upper abdominal pain, or dark urine. I documented that a follow-up appointment is scheduled in four weeks to review the full panel and decide on suitability for DMARD initiation.\n\nEnd of dictation.\"\n",
                "dataSource": "BigHand",
                "highlights": [
                    {
                        "text": "specifically an ALT of 78 U/L, which is nearly twice the upper limit of normal.",
                        "color": "yellow"
                    },
                    {
                        "text": "The pattern continues to suggest a hepatocellular injury, consistent with the background suspicion of metabolic dysfunction-associated steatotic liver disease MASLD and the long-standing metabolic risk factors we documented previously, including type 2 diabetes, suboptimal glycaemic control, and moderate alcohol intake.",
                        "color": "yellow"
                    },
                    {
                        "text": "Methotrexate is a highly effective DMARD, but one with well-established hepatotoxic potential.",
                        "color": "yellow"
                    },
                    {
                        "text": "Even mild instability in LFTs increases risk, but when the baseline ALT is already elevated, as in Sarah\u00e2\u20ac\u2122s case, the risk of clinically meaningful injury potentially even severe DILI rises significantly.",
                        "color": "red"
                    },
                    {
                        "text": "In her scenario, the first hit is MASLD, which causes chronic low-grade hepatic inflammation.",
                        "color": "yellow"
                    },
                    {
                        "text": "Adding Methotrexate, which itself generates oxidative stress and can create hepatic stellate activation, easily tips the balance into injury.",
                        "color": "red"
                    },
                    {
                        "text": "The risk is not theoretical: the evidence base clearly shows that patients with MASLD are more vulnerable to Methotrexate-induced hepatic fibrosis and steatohepatitis.",
                        "color": "red"
                    },
                    {
                        "text": "I explained that viral hepatitis particularly hepatitis B core antibody positivity would fundamentally change monitoring requirements and contraindications.",
                        "color": "red"
                    },
                    {
                        "text": "Autoimmune hepatitis must also be excluded because Methotrexate is strongly contraindicated in active AIH, as it can both exacerbate hepatic inflammation and mask clinical symptoms until severe injury has occurred.",
                        "color": "red"
                    },
                    {
                        "text": "\u00e2\u20ac\u00a2 Viral serology HBsAg, hepatitis B core total antibody, hepatitis C antibody, and HEV IgG.",
                        "color": "yellow"
                    },
                    {
                        "text": "I explained that even if surface antigen is negative, a positive core antibody would require modification of future DMARD regimens, and possible prophylaxis, depending on risk.",
                        "color": "yellow"
                    },
                    {
                        "text": " Autoimmune screen ANA, ASMA, LKM-1 and total IgG, which allow us to reliably detect autoimmune hepatitis patterns.",
                        "color": "yellow"
                    },
                    {
                        "text": " Metabolic screen ferritin, transferrin saturation and alpha-1-antitrypsin levels, to exclude haemochromatosis and AAT deficiency.",
                        "color": "yellow"
                    },
                    {
                        "text": "Both of these conditions increase susceptibility to DILI and accelerate fibrosis if Methotrexate is used.",
                        "color": "red"
                    },
                    {
                        "text": " And a repeat full LFT panel in four weeks, which will help differentiate between a stable chronic mild MASLD pattern versus a dynamic or inflammatory process.",
                        "color": "yellow"
                    },
                    {
                        "text": "I made it clear to Sarah that if this workup shows viral or autoimmune pathology, Methotrexate would be absolutely contraindicated and we would need to pursue alternative RA management, likely hydroxychloroquine or a biologic agent depending on rheumatology input.",
                        "color": "red"
                    },
                    {
                        "text": "If the panel is negative, but ALT remains raised, we will still need to be extremely cautious, as underlying steatohepatitis, even if non-viral and non-autoimmune, carries higher risk.",
                        "color": "red"
                    },
                    {
                        "text": "I also advised Sarah strongly to avoid all NSAID use for now particularly ibuprofen which she normally takes up to five times a week.",
                        "color": "yellow"
                    },
                    {
                        "text": "NSAIDs do carry their own hepatotoxic potential, and we must avoid any additional hepatic irritants until her LFTs settle and the screening is complete.",
                        "color": "yellow"
                    },
                    {
                        "text": "Finally, I confirmed that she should contact the surgery promptly if she develops any new symptoms such as nausea, jaundice, upper abdominal pain, or dark urine.",
                        "color": "red"
                    }
                ]
            }
        }
    },
    {
        "id": "raw-radiology-ct-chest-1",
        "type": "component",
        "componentType": "RadiologyImage",
        "description": "Left Hand X-ray \u2013 PA View",
        "content": {
            "title": "Left Hand X-ray - Encounter 6",
            "component": "RadiologyImage",
            "props": {
                "encounterNumber": 6,
                "date": "2024-08-12",
                "studyType": "Left Hand X-ray \u2013 PA View",
                "provider": "Dr. L. Andrews",
                "specialty": "Radiology",
                "imageUrl": "/images/radio-image.png",
                "dataSource": "Radiology PACS"
            }
        }
    },
    {
        "id": "raw-radiology-ultrasound-liver-1",
        "type": "component",
        "componentType": "RadiologyImage",
        "description": "CT Abdomen \u2013 Axial View with Liver ROIs",
        "content": {
            "title": "CT Abdomen \u2013 Axial View with Liver ROIs",
            "component": "RadiologyImage",
            "props": {
                "encounterNumber": 6,
                "date": "2024-08-12",
                "studyType": "CT Abdomen \u2013 Axial View Complete",
                "provider": "S. Patel",
                "specialty": "Sonography",
                "imageUrl": "/images/liver.png",
                "dataSource": "Radiology PACS"
            }
        }
    },
    {
        "id": "sidebar-1",
        "type": "component",
        "componentType": "Sidebar",
        "content": {
            "props": {
                "patientData": {
                    "patient": {
                        "name": "Sarah Miller",
                        "date_of_birth": "1981-06-03",
                        "age": 43,
                        "sex": "Female",
                        "age_at_first_encounter": 43,
                        "identifiers": {
                            "mrn": "SM43850603"
                        }
                    },
                    "riskLevel": "high",
                    "primaryDiagnosis": "Severe Drug-Induced Liver Injury (Methotrexate-related) on MASLD background",
                    "problem_list": [
                        {
                            "name": "Type 2 Diabetes Mellitus",
                            "status": "active"
                        },
                        {
                            "name": "Essential Hypertension",
                            "status": "active"
                        },
                        {
                            "name": "Rheumatoid Arthritis",
                            "status": "active"
                        },
                        {
                            "name": "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "status": "active"
                        },
                        {
                            "name": "Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "status": "active"
                        },
                        {
                            "name": "Class I Obesity (BMI 32.0)",
                            "status": "active"
                        }
                    ]
                }
            }
        }
    },
    {
        "id": "encounter-track-1",
        "type": "component",
        "componentType": "EncounterTrack",
        "content": {
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "type": "General Practice",
                        "provider": "Dr. P. Stevens",
                        "chief_complaint": "Increased fatigue over the past 4-5 months.",
                        "medications": [
                            "Metformin 1000mg BD",
                            "Ramipril 5mg OD",
                            "Ibuprofen 4-5x/week"
                        ],
                        "impression": "Suboptimal control of T2DM/HTN, Chronic Fatigue Syndrome possibly related to MASLD. Mild effusion in right MCP joint.",
                        "differential_diagnosis": [
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Uncontrolled T2DM",
                            "Rheumatoid Arthritis (conservatively managed)"
                        ],
                        "notes": "Baseline ALT 78 U/L detected. Patient reports debilitating fatigue. Advised 5% weight loss target.",
                        "casual_reason": "Elevated ALT (78 U/L) and fatigue attributed to underlying Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) driven by Class I obesity (BMI 32.0) and suboptimal T2DM control."
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "type": "General Practice",
                        "provider": "Dr. P. Stevens",
                        "chief_complaint": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment.",
                        "medications": [
                            "Metformin 1000mg BD",
                            "Ramipril 5mg OD"
                        ],
                        "impression": "Review of abnormal LFTs. Suspicion of MASLD. Decision to defer Methotrexate initiation pending liver safety workup.",
                        "differential_diagnosis": [
                            "MASLD (likely)",
                            "Viral Hepatitis (to be excluded)",
                            "Autoimmune Hepatitis (to be excluded)"
                        ],
                        "notes": "ALT 78 U/L. Explicitly advised against NSAID use. Ordered comprehensive hepatitis and autoimmune panel.",
                        "casual_reason": "Persistent ALT elevation (78 U/L) confirms ongoing hepatocellular inflammation, likely due to unmanaged MASLD, necessitating deferral of hepatotoxic medication (MTX)."
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "type": "General Practice",
                        "provider": "Dr. P. Stevens",
                        "chief_complaint": "Follow-up regarding the normalization of liver function tests (LFTs) and potential initiation of Methotrexate.",
                        "medications": [
                            "Metformin 1000mg BD",
                            "Ramipril 5mg OD"
                        ],
                        "impression": "Normalization of LFTs (ALT 35 U/L). Hepatitis/Autoimmune workup negative. Clearance granted for Methotrexate initiation.",
                        "differential_diagnosis": [
                            "Transient liver enzyme elevation (resolved)",
                            "MASLD (stable)"
                        ],
                        "notes": "Full normalization confirmed. Patient cleared for MTX start on 2024-06-03. Strict monitoring schedule established.",
                        "casual_reason": "Normalization of ALT (35 U/L) attributed to successful lifestyle modifications (dietary changes, weight loss) and resolution of the transient MASLD flare."
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "type": "General Practice",
                        "provider": "Dr. P. Stevens",
                        "chief_complaint": "Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.",
                        "medications": [
                            "Methotrexate 7.5mg weekly (Start)",
                            "Folic Acid 5mg weekly (Start)"
                        ],
                        "impression": "Initiation of DMARD therapy for RA. Patient educated on hepatotoxicity risks and monitoring requirements.",
                        "differential_diagnosis": [
                            "Rheumatoid Arthritis (Active)"
                        ],
                        "notes": "MTX started at 7.5mg. Baseline LFTs normal. Next check scheduled for July 15.",
                        "casual_reason": "Baseline stability established; no biomarker derangement yet as Methotrexate therapy is just commencing."
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "type": "General Practice",
                        "provider": "Dr. P. Stevens",
                        "chief_complaint": "Routine Methotrexate (MTX) monitoring. Reports of new intermittent nausea and increased fatigue.",
                        "medications": [
                            "Methotrexate 5mg weekly (Reduced Dose)",
                            "Folic Acid 5mg weekly"
                        ],
                        "impression": "Significant elevation in ALT to 185 U/L (4.6x ULN). Intermittent nausea reported. RA symptoms improved.",
                        "differential_diagnosis": [
                            "Methotrexate-induced DILI",
                            "MASLD flare"
                        ],
                        "notes": "CRITICAL DECISION: MTX reduced to 5mg rather than discontinued despite ALT >3x ULN. Hepatology referral initiated (Routine).",
                        "casual_reason": "Sharp rise in ALT to 185 U/L (4.6x ULN) indicates acute hepatocellular injury caused by Methotrexate toxicity, exacerbated by the underlying steatotic liver substrate."
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "type": "Emergency Department",
                        "provider": "Dr. P. Stevens / ED Registrar",
                        "chief_complaint": "Urgent review for new onset jaundice, dark urine, and constant, severe nausea leading to anorexia.",
                        "medications": [
                            "N-acetylcysteine (NAC) Infusion (Started)"
                        ],
                        "impression": "Severe Acute Drug-Induced Liver Injury (DILI) with developing cholestasis. Jaundice and dark urine present.",
                        "differential_diagnosis": [
                            "Severe hepatocellular DILI (MTX-related)",
                            "Biliary obstruction (ruled out by USG)"
                        ],
                        "notes": "Crisis point: ALT 490 U/L, Bilirubin 110 \u00b5mol/L. MTX stopped immediately. Admitted for NAC protocol.",
                        "casual_reason": "Massive spike in ALT (490 U/L) and onset of jaundice (Bilirubin 110 \u00b5mol/L) caused by cumulative Methotrexate toxicity following the failure to discontinue the drug during the July warning signs."
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "type": "Inpatient Hepatology",
                        "provider": "Dr. R. Sharma",
                        "chief_complaint": "Inpatient review for Severe Drug-Induced Liver Injury (DILI) stabilization.",
                        "medications": [
                            "Ursodeoxycholic Acid (UDCA) 500mg BD",
                            "NAC Protocol (Completing Aug 17)"
                        ],
                        "impression": "Severe cholestatic DILI on background of MASH. RUCAM score 9/10. Synthetic function preserved (INR 1.1).",
                        "differential_diagnosis": [
                            "Severe DILI (Cholestatic phase)",
                            "MASH"
                        ],
                        "notes": "MTX permanently contraindicated. Bilirubin peaked at 190 \u00b5mol/L. Fibroscan ordered for 3 months post-discharge.",
                        "casual_reason": "Rising Bilirubin (190 \u00b5mol/L) despite falling ALT reflects the 'cholestatic phase' of recovery, where bile excretion remains impaired even as active hepatocellular necrosis subsides following MTX cessation."
                    }
                ],
                "showHandles": true
            }
        }
    },
    {
        "id": "medication-track-1",
        "type": "component",
        "componentType": "MedicationTrack",
        "content": {
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05"
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01"
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06"
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03"
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15"
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12"
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15"
                    }
                ],
                "medications": [
                    {
                        "name": "Ramipril",
                        "startDate": "2020-01-01",
                        "endDate": "2025-02-15",
                        "dose": "5mg OD",
                        "indication": "Hypertension"
                    },
                    {
                        "name": "Metformin",
                        "startDate": "2019-01-01",
                        "endDate": "2025-02-15",
                        "dose": "1000mg BD",
                        "indication": "T2DM"
                    },
                    {
                        "name": "Methotrexate",
                        "startDate": "2024-06-03",
                        "endDate": "2024-07-15",
                        "dose": "7.5mg weekly",
                        "indication": "RA"
                    },
                    {
                        "name": "Methotrexate",
                        "startDate": "2024-07-15",
                        "endDate": "2024-08-12",
                        "dose": "5mg weekly",
                        "indication": "RA (Dose reduced due to ALT spike)"
                    },
                    {
                        "name": "Folic Acid",
                        "startDate": "2024-06-03",
                        "endDate": "2024-08-17",
                        "dose": "5mg weekly",
                        "indication": "MTX supplementation"
                    },
                    {
                        "name": "N-acetylcysteine (NAC)",
                        "startDate": "2024-08-12",
                        "endDate": "2024-08-17",
                        "dose": "IV Protocol",
                        "indication": "Acute Liver Injury"
                    },
                    {
                        "name": "Ursodeoxycholic Acid",
                        "startDate": "2024-08-15",
                        "endDate": "2025-2-25",
                        "dose": "500mg BD",
                        "indication": "Cholestasis"
                    }
                ],
                "showHandles": true
            }
        },
        "description": "A review of Sarah Miller\u2019s medication history shows one clear hepatotoxic agent capable of causing her pattern of liver injury: Methotrexate (MTX). Prior to MTX initiation, her routine medications included Metformin, Ramipril, and Folic Acid. The timeline strongly supports MTX as the causative agent: her ALT was normal (35 U/L) before starting MTX, then rose to 185 U/L six weeks later, and subsequently peaked at 490 U/L with bilirubin at 110\u2013190 \u03bcmol/L. This progression, combined with the absence of viral, autoimmune, or metabolic liver disease, and confirmed by a RUCAM score of 9/10 during hepatology review, indicates Methotrexate as the definitive cause. No other medication in her regimen shows a plausible pattern or timing consistent with the severity and type of liver injury observed."
    },
    {
        "id": "lab-track-1",
        "type": "component",
        "componentType": "LabTrack",
        "description": "'\n- Which liver function tests are elevated?\n- When did these become abnormal?\n- How has her diabetes control been?\n\nLab Track Description: Liver Function and Diabetes Monitoring (March\u2013August 2024)\n\nThis component tracks longitudinal laboratory data for Liver Function Tests (LFTs) and Diabetes Control (HbA1c) across seven encounters between 2024-03-05 and 2024-08-15.\n\nSummary of Trends:\n\nLiver Enzymes: The patient exhibited a biphasic pattern. Mild elevations in March normalized by May, followed by a severe, progressive spike in ALT and AST starting in July and peaking in August.\n\nBilirubin: Remained normal until a sharp increase in August, indicating late-stage acute injury.\n\nSynthetic Function: INR remained stable and within reference range (0.8\u20131.2) throughout the period.\n\nDiabetes: HbA1c levels remained consistently above the reference range, indicating suboptimal glycemic control.\n\nClinical Q&A:\n\nQ: Which liver function tests are elevated?\n\nA: ALT, AST, and Total Bilirubin are significantly elevated.\n\nALT peaked at 490 U/L (Ref: 0-40).\n\nAST peaked at 350 U/L (Ref: 0-35).\n\nTotal Bilirubin peaked at 190 \u00b5mol/L (Ref: 0-21).\n\nNote: INR remained normal (1.1), indicating preserved clotting function.\n\nQ: When did these become abnormal?\n\nA: While there was a mild, transient elevation in March (ALT 78), the tests normalized in May. The significant abnormality began on July 15, 2024, when ALT spiked to 185 U/L and AST to 130 U/L. This worsened drastically by August 12, 2024, when Bilirubin also spiked to 110 \u00b5mol/L.\n\nQ: How has her diabetes control been?\n\nA: Her diabetes control has been suboptimal and slightly worsening.\n\nHbA1c values were consistently elevated above the reference maximum of 48 mmol/mol.\n\nValues recorded were: 58 mmol/mol (March), 56 mmol/mol (May), and 60 mmol/mol (July).\n'",
        "content": {
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05"
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01"
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06"
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03"
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15"
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12"
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15"
                    }
                ],
                "labs": [
                    {
                        "biomarker": "ALT",
                        "unit": "U/L",
                        "referenceRange": {
                            "min": 0,
                            "max": 40
                        },
                        "values": [
                            {
                                "t": "2024-03-05T10:15:00",
                                "value": 78
                            },
                            {
                                "t": "2024-05-06T09:00:00",
                                "value": 35
                            },
                            {
                                "t": "2024-07-15T14:00:00",
                                "value": 185
                            },
                            {
                                "t": "2024-08-12T09:30:00",
                                "value": 490
                            },
                            {
                                "t": "2024-08-15T10:00:00",
                                "value": 420
                            }
                        ]
                    },
                    {
                        "biomarker": "AST",
                        "unit": "U/L",
                        "referenceRange": {
                            "min": 0,
                            "max": 35
                        },
                        "values": [
                            {
                                "t": "2024-03-05T10:15:00",
                                "value": 55
                            },
                            {
                                "t": "2024-05-06T09:00:00",
                                "value": 30
                            },
                            {
                                "t": "2024-07-15T14:00:00",
                                "value": 130
                            },
                            {
                                "t": "2024-08-12T09:30:00",
                                "value": 350
                            }
                        ]
                    },
                    {
                        "biomarker": "Total Bilirubin",
                        "unit": "\u00b5mol/L",
                        "referenceRange": {
                            "min": 0,
                            "max": 21
                        },
                        "values": [
                            {
                                "t": "2024-03-05T10:15:00",
                                "value": 12
                            },
                            {
                                "t": "2024-07-15T14:00:00",
                                "value": 15
                            },
                            {
                                "t": "2024-08-12T09:30:00",
                                "value": 110
                            },
                            {
                                "t": "2024-08-15T10:00:00",
                                "value": 190
                            }
                        ]
                    },
                    {
                        "biomarker": "INR",
                        "unit": "ratio",
                        "referenceRange": {
                            "min": 0.8,
                            "max": 1.2
                        },
                        "values": [
                            {
                                "t": "2024-03-05T10:15:00",
                                "value": 1
                            },
                            {
                                "t": "2024-07-15T14:00:00",
                                "value": 1.05
                            },
                            {
                                "t": "2024-08-12T09:30:00",
                                "value": 1.1
                            },
                            {
                                "t": "2024-08-15T10:00:00",
                                "value": 1.1
                            }
                        ]
                    },
                    {
                        "biomarker": "HbA1c",
                        "unit": "mmol/mol",
                        "referenceRange": {
                            "min": 0,
                            "max": 48
                        },
                        "values": [
                            {
                                "t": "2024-03-05T10:15:00",
                                "value": 58
                            },
                            {
                                "t": "2024-05-06T09:00:00",
                                "value": 56
                            },
                            {
                                "t": "2024-07-15T14:00:00",
                                "value": 60
                            }
                        ]
                    }
                ],
                "showHandles": true
            }
        }
    },
    {
        "id": "risk-track-1",
        "type": "component",
        "componentType": "RiskTrack",
        "content": {
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05"
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01"
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06"
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03"
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15"
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12"
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15"
                    }
                ],
                "risks": [
                    {
                        "t": "2024-03-05T10:15:00",
                        "riskScore": 0.4,
                        "factors": [
                            "Baseline ALT 78",
                            "BMI 32",
                            "T2DM",
                            "MASLD suspected"
                        ]
                    },
                    {
                        "t": "2024-05-06T09:00:00",
                        "riskScore": 0.2,
                        "factors": [
                            "ALT normalized (35)",
                            "Hepatitis screen negative",
                            "Cleared for MTX"
                        ]
                    },
                    {
                        "t": "2024-07-15T14:00:00",
                        "riskScore": 0.8,
                        "factors": [
                            "ALT 185 (Critical)",
                            "Nausea",
                            "MTX continued (reduced dose)"
                        ]
                    },
                    {
                        "t": "2024-08-12T09:30:00",
                        "riskScore": 9.5,
                        "factors": [
                            "ALT 490",
                            "Bilirubin 110",
                            "Jaundice",
                            "Severe DILI"
                        ]
                    },
                    {
                        "t": "2024-08-15T10:00:00",
                        "riskScore": 8,
                        "factors": [
                            "Bilirubin 190",
                            "ALT dropping (420)",
                            "INR stable",
                            "On NAC"
                        ]
                    }
                ],
                "showHandles": true
            }
        }
    },
    {
        "id": "key-events-track-1",
        "type": "component",
        "componentType": "KeyEventsTrack",
        "description": "'Case :\n11. What other treatment options are available to Sarah Miller for her rheumatoid\narthritis, which does not affect the liver?\n\nGiven Sarah Miller\u2019s severe Methotrexate-induced DILI, she now requires rheumatoid arthritis treatments that do not pose liver toxicity risks. The safest non-hepatotoxic options include Hydroxychloroquine, which has minimal hepatic metabolism and is considered one of the safest DMARDs for patients with liver impairment, and Sulfasalazine, which carries a very low risk of hepatotoxicity and is commonly used when Methotrexate is contraindicated. In more active disease, biologic agents such as TNF-\u03b1 inhibitors (e.g., Etanercept, Adalimumab) or IL-6 inhibitors (e.g., Tocilizumab) are viable because they bypass hepatic metabolism and do not typically worsen underlying liver disease.\n\nShort-term low-dose corticosteroids may also be used as bridging therapy to control symptoms while transitioning to a safer long-term agent. These recommendations are consistent with the hepatology team\u2019s plan in Encounter 7, where Methotrexate was permanently contraindicated and a referral was made to select a non-hepatotoxic DMARD alternative\n'",
        "content": {
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05"
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01"
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06"
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03"
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15"
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12"
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15"
                    }
                ],
                "events": [
                    {
                        "event": "Baseline Risk Identified",
                        "t": "2024-03-05T10:15:00",
                        "note": "ALT 78 detected. MTX deferred. MASLD suspected."
                    },
                    {
                        "event": "MTX Initiation",
                        "t": "2024-06-03T11:30:00",
                        "note": "MTX started 7.5mg/week after LFT normalization."
                    },
                    {
                        "event": "Missed Warning Signal",
                        "t": "2024-07-15T14:00:00",
                        "note": "ALT spiked to 185 (4.6x ULN). MTX reduced instead of stopped."
                    },
                    {
                        "event": "Crisis Presentation",
                        "t": "2024-08-12T09:30:00",
                        "note": "Jaundice, dark urine, anorexia. ALT 490. MTX stopped."
                    },
                    {
                        "event": "Hospital Admission",
                        "t": "2024-08-12T14:00:00",
                        "note": "Admitted for NAC infusion. USG confirms MASLD, rules out obstruction."
                    },
                    {
                        "event": "Peak Cholestasis",
                        "t": "2024-08-15T10:00:00",
                        "note": "Bilirubin peaks at 190 \u00b5mol/L. Synthetic function preserved."
                    }
                ],
                "showHandles": true
            }
        }
    },
    {
        "id": "item-1765199420012-g2ihip",
        "type": "legal-compliance",
        "content": "Legal Compliance Report",
        "legalData": {
            "identification_verification": {
                "patient_id": "SM43850603",
                "patient_name": "Sarah Miller",
                "dob": "1981-06-03",
                "mrn": "SM43850603",
                "forms": [
                    {
                        "form_id": "1a",
                        "checks": true,
                        "notes": ""
                    },
                    {
                        "form_id": "1b",
                        "checks": true,
                        "notes": "Bristol North Family Practice, Dr P. StevensNotes: GP practice initiated MTX monitoring andperformed first abnormal LFT assessment."
                    },
                    {
                        "form_id": "1c",
                        "checks": true,
                        "notes": "Patient was fully alert, oriented to time, place, person.Demonstrated accurate understanding of her condition (\u201cMy liver numbers are high because of the methotrexate\u201d)."
                    },
                    {
                        "form_id": "1d",
                        "checks": true,
                        "notes": "NOK: Husband \u2013 Daniel Miller (07782 113847)Notes: Contact details confirmed and updated in ED system."
                    },
                    {
                        "form_id": "1e",
                        "checks": true,
                        "notes": "21 Hawthorne Road, Bristol BS4 8QPNotes: Matches GP record and patient verbal confirmation."
                    }
                ]
            },
            "compliant_consent": {
                "forms": [
                    {
                        "form_id": "2a",
                        "checks": true,
                        "notes": "'Risks discussed included hepatotoxicity, severe DILI, bone marrow suppression, increased infection risk, methotrexate pneumonitis, mucositis, nausea/vomiting, and teratogenicity.\nPatient-specific risk modifiers:\nKnown MASLD/MASH on prior ultrasound\nOverweight (BMI ~31)\nT2DM with mild hyperglycaemia\nRegular NSAID use for joint pain\nPrior mildly elevated ALT before MTX initiation\n\nPatient acknowledged understanding that her liver disease increased her risk of MTX injury."
                    },
                    {
                        "form_id": "2b",
                        "checks": true,
                        "notes": "'Details: Hydroxychloroquine, Sulfasalazine, Leflunomide, and biologic DMARDs were discussed. Patient declined biologics at the time due to concerns about injections and infection risk.'"
                    },
                    {
                        "form_id": "2c",
                        "checks": true,
                        "notes": "'Patient Response (verbatim):\n\u201cIf my eyes or skin go yellow, or if I feel very sick or lose my appetite, I must stop methotrexate right away and tell the GP.\u201d\nInterpretation: Patient demonstrated good understanding."
                    },
                    {
                        "form_id": "2d",
                        "checks": true,
                        "notes": "'At ALT 185 U/L (\u22484.6 \u00d7 ULN), national MTX guidance requires immediate cessation, but the GP opted to reduce dose from 10mg to 5mg, citing RA flare and normal INR.\nNo documentation shows the patient was informed that continuing MTX at any dose was outside standard safety guidance."
                    }
                ]
            },
            "mental_capacity": {
                "forms": [
                    {
                        "form_id": "3a",
                        "checks": true,
                        "notes": "'Reason: Marked jaundice and nausea prompted assessment."
                    },
                    {
                        "form_id": "3b",
                        "checks": true,
                        "notes": "'Outcome: No impairment of mind/brain; retained and weighed all information."
                    }
                ]
            },
            "duty_candour": {
                "forms": [
                    {
                        "form_id": "4a",
                        "checks": true,
                        "notes": "'Nature of Harm:\nSevere hepatocellular DILI\nJaundice (T-bili significantly elevated)\nHospital admission required\nRisk of hepatic failure\nPreventability factor: delayed MTX cessation\n"
                    },
                    {
                        "form_id": "4b",
                        "checks": true,
                        "notes": "'Notes: GP expressed regret for delayed cessation and explained how earlier withdrawal might have prevented deterioration."
                    },
                    {
                        "form_id": "4c",
                        "checks": true,
                        "notes": "'Patient was advised that persisting with MTX after significant ALT rise likely contributed to further liver injury."
                    },
                    {
                        "form_id": "4d",
                        "checks": true,
                        "notes": "'Notes: Required but not found in any record. Should be generated and sent to patient."
                    }
                ]
            },
            "guideline_adherence": {
                "forms": [
                    {
                        "form_id": "5a",
                        "checks": true,
                        "notes": "'Details:\nDiagnosis and management consistent with EASL DILI 2023\nMASLD considerations per BSG 2024\nAppropriate fibrosis risk assessment planned\n"
                    },
                    {
                        "form_id": "5b",
                        "checks": true,
                        "notes": "'GP note: \u201cWill reduce dose and re-check bloods, RA flaring.\u201d\nNo documentation referencing national MTX safety thresholds or rationale for deviating from them.\n"
                    },
                    {
                        "form_id": "5c",
                        "checks": true,
                        "notes": "'Raw Explanation:\nAt ALT >3\u00d7 ULN, immediate cessation is mandatory. GP reduced dose instead. INR normal but irrelevant to hepatocellular toxicity. This exposed patient to avoidable ongoing injury.\n"
                    }
                ]
            },
            "red_flags_diagnosis": {
                "flag_list": [
                    {
                        "flag": "Viral hepatitis excluded",
                        "notes": "HBV sAg, HBcAb, HCV Ab negative."
                    },
                    {
                        "flag": "Autoimmune hepatitis excluded",
                        "notes": "ANA, ASMA negative; IgG normal."
                    },
                    {
                        "flag": "Obstruction excluded",
                        "notes": "Ultrasound with normal CBD (4mm), no gallstones."
                    },
                    {
                        "flag": "Alcoholic hepatitis excluded",
                        "notes": "History inconsistent; LFT pattern hepatocellular."
                    },
                    {
                        "flag": "Sepsis ruled out",
                        "notes": "No fever, normal WBC, stable vitals."
                    },
                    {
                        "flag": "Ischaemic hepatitis excluded",
                        "notes": "No hypotension, lactate normal."
                    },
                    {
                        "flag": "Metabolic causes excluded",
                        "notes": "No Wilson\u2019s risk; age >40."
                    }
                ],
                "diagnosis": "MTX-induced hepatocellular DILI (RUCAM score = 9, \u201chighly probable\u201d) superimposed on pre-existing MASH."
            },
            "procedural": {
                "forms": [
                    {
                        "form_id": "7a",
                        "checks": null,
                        "notes": "Notes: ID confirmed; indications reviewed; allergies checked"
                    },
                    {
                        "form_id": "7b",
                        "checks": null,
                        "notes": "INR: 1.1 Notes: No bleeding risk; safe for abdominal ultrasound."
                    },
                    {
                        "form_id": "7c",
                        "checks": null,
                        "notes": "'Dosing Details:\n\n150 mg/kg \u2192 50 mg/kg \u2192 100 mg/kg\n\nNo anaphylactoid response\n\nCompleted fully\n"
                    },
                    {
                        "form_id": "7d",
                        "checks": null,
                        "notes": "'Details:\n\nGCS 15 throughout\n\nNo HE\n\nLFTs trended daily (ALT extremely elevated but stable trajectory under NAC)\n"
                    }
                ]
            },
            "safety_net": {
                "forms": [
                    {
                        "form_id": "8a",
                        "checks": true,
                        "notes": "Notes: MTX added to allergy/contraindicated list."
                    },
                    {
                        "form_id": "8b",
                        "checks": null,
                        "notes": "'Advice Given:\nImmediate ED return if:\n\nJaundice worsens\n\nVomiting persists\n\nMental status changes\n\nSevere abdominal pain\n\nBlack stool or GI bleed\n\nFever\n\nReduced urine output\n"
                    },
                    {
                        "form_id": "8c",
                        "checks": null,
                        "notes": "'Method: Teach-back; patient accurately repeated red-flag symptoms."
                    }
                ]
            },
            "communication": {
                "forms": [
                    {
                        "form_id": "9a",
                        "checks": true,
                        "notes": "Method: Nervecentre automatic report + hepatology outcome letter."
                    },
                    {
                        "form_id": "9b",
                        "checks": true,
                        "notes": "Received By: ED medical registrar Summary: \u201cSuspected severe MTX DILI, urgent NAC indicated.\u201d"
                    },
                    {
                        "form_id": "9c",
                        "checks": true,
                        "notes": "Critical Abnormalities: ALT 185 \u2192 490; bilirubin significantly raised; ALT >25\u00d7 ULN at admission"
                    }
                ]
            },
            "attendance": {
                "checks": true,
                "forms": [
                    {
                        "appointment": "",
                        "notes": ""
                    },
                    {
                        "appointment": "",
                        "notes": ""
                    }
                ]
            },
            "practitioner": {
                "forms": [
                    {
                        "form_id": "11a",
                        "checks": true,
                        "notes": ""
                    },
                    {
                        "form_id": "11b",
                        "checks": true,
                        "notes": "Notes: MTX monitoring and NAC administration appropriate for GP/ED/hepatology."
                    }
                ]
            },
            "incident": {
                "forms": [
                    {
                        "form_id": "12a",
                        "checks": true,
                        "notes": "Incident Description: Delayed cessation of methotrexate despite ALT rising to ~185 U/L (\u22484.6\u00d7 ULN). This represents deviation from MTX monitoring safety standards and likely contributed to subsequent severe DILI requiring admission."
                    },
                    {
                        "form_id": "12b",
                        "checks": true,
                        "notes": "Notes: No evidence of DATIX in system. Should be completed for governance learning regarding MTX monitoring compliance."
                    }
                ]
            },
            "signature": {
                "patient_signature": "Sarah Miller",
                "practitioner_signature": "Dr. P. Stevens"
            }
        }
    },
    {
        "id": "doctor-note-1765199442702",
        "type": "doctor-note",
        "noteData": {
            "content": "",
            "timestamp": "2025-12-08T13:10:42.702Z"
        }
    }
]